

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/Caplus-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of Caplus documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/Caplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:01:45 ON 08 DEC 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.26

1.26

FILE 'REGISTRY' ENTERED AT 17:05:15 ON 08 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0
DICTIONARY FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\106228331.str



chain nodes :

7 8 9 14 15 16 17 23

ring nodes :

1 2 3 4 5 6 13 18 19 20 21 22

chain bonds :

2-15 3-14 6-7 7-8 7-13 8-9 14-16 15-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-18 13-22 18-19 19-20 20-21 21-22

exact/norm bonds :

2-15 3-14 6-7 7-8 7-13 8-9 14-16

exact bonds :

15-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-18 13-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 13:Atom
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS 24:CLASS

Generic attributes :

9:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :

Node 9: Limited

C,C5

N,N1

O,O0


S,S0

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:05:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4714 TO ITERATE

42.4% PROCESSED 2000 ITERATIONS

11 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 90163 TO 98397

PROJECTED ANSWERS: 213 TO 823

L2 11 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:05:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 94997 TO ITERATE

100.0% PROCESSED 94997 ITERATIONS
SEARCH TIME: 00.00.01

401 ANSWERS

L3 401 SEA SSS FUL L1

=> s l3 and caplus/lc
49135313 CAPLUS/LC

L4 401 L3 AND CAPLUS/LC

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

165.93

167.19

FILE 'CAPLUS' ENTERED AT 17:05:40 ON 08 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 7 Dec 2005 (20051207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4

L5 8 L4


=> d ibib abs hitstr 1-8

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:588900 CAPLUS
 DOCUMENT NUMBER: 143:115450
 TITLE: Preparation of phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs, useful as cognition enhancers
 INVENTOR(S): Schumacher, Richard; Hopper, Allen; Dunn, Robert; Kuester, Erik; Tehim, Ashok; Renau, Thomas E.;
 Caroon, Joan; Talamas, Francisco; Labadie, Sharada
 PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061458	A2	20050707	WO 2004-US41068	20041210
WO 2005061458	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2005222207 A1 20051006 US 2004-8775 20041210
 PRIORITY APPLN. INFO.: US 2003-528486P P 20031211


OTHER SOURCE(S): MARPAT 143:115450
 GI



AB PDE4 inhibition (no data) is achieved by novel compds., e.g., N-substituted diarylamine analogs (shown as I; variables defined below; e.g. 3-[N-([6-(cyclopropylmethoxy)-5-methoxypyridin-2-yl)]-N-[(pyridin-3-


L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 N ylmethylamino]benzoic acid (shown as II)). For I: A, B and D are each
 or CR5: R1 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR6, COR6, CONR6, or NR6COR10; R2 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR7, COR6, CONR6, or NR6COR10; R3 is C1-8 (un)substituted (un)branched alkyl, a partially unsatd. C5-14 carbocycle-alkyl, C7-19 arylalkyl or heteroarylalkyl group; R4 is C3-10 cycloalkyl, C6-14 aryl, heteroaryl having 5-10 ring atoms, a heterocyclic group, a heterocyclealkyl group; addnl. details including provisoes are given in the claims. Although the methods of prepn. are not claimed, .apprx.13 example prepn. of I and intermediates are included. For example, N-(3-chlorophenyl)-N-[5-methoxy-6-[(3R)-tetrahydrofuran-3-yl]oxy]pyridin-2-yl]pyridine-3-methanamine was prepd. from 6-iodo-3-methoxy-2-[(3R)-tetrahydrofuran-3-yl]oxy]pyridine and 3-chlorophenyl-N-(3-pyridinylmethyl)amine.
 IT 857295-12-6P, 3-[N-(3-Cyclopentyl-2-fluoro-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-13-7P, 3-[N-(2-Chloro-5-cyclopentyl-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-14-8P, 4-[N-(2-Chloro-5-cyclopentyl-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-15-9P, 4-[N-(3-Cyclopentyl-2-fluoro-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-17-1P, 4-[N-(5-Cyclopentyl-4-methoxy-2-methylphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-18-2P, 3-[N-(5-Cyclopentyl-4-methoxy-2-methylphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-19-3P, N-(5-Cyclopentyl-4-methoxy-2-methylphenyl)-N-phenylpyridine-3-methanamine 857295-20-6P, 4-[N-(5-Cyclopentyl-2-fluoro-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-21-7P, 3-[N-(5-Cyclopentyl-2-fluoro-4-methoxyphenyl)-N-[(pyridin-3-yl)methylamino]benzoic acid 857295-22-8P, N-(5-Cyclopentyl-2-fluoro-4-methoxyphenyl)-N-phenylpyridine-3-methanamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs, useful as cognition enhancers)

857295-12-6 CAPLUS
 CN Benzoic acid, 3-[(2-chloro-5-(cyclopentyl-4-methoxyphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)




857295-13-7 CAPLUS
 CN Benzoic acid, 3-[(2-chloro-5-(cyclopentyl-4-methoxyphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



857295-14-8 CAPLUS
 CN Benzoic acid, 4-[(2-chloro-5-(cyclopentyl-4-methoxyphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)




857295-15-9 CAPLUS
 CN Benzoic acid, 4-[(3-(cyclopentyl-2-fluoro-4-methoxyphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)




857295-17-1 CAPLUS
 CN Benzoic acid, 4-[(5-(cyclopentyl-4-methoxy-2-methylphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




857295-18-2 CAPLUS
 CN Benzoic acid, 3-[(5-(cyclopentyl-4-methoxy-2-methylphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)




857295-19-3 CAPLUS
 CN 3-Pyridinemethanamine, N-(5-(cyclopentyl-4-methoxy-2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




857295-20-6 CAPLUS
 CN Benzoic acid, 4-[(5-(cyclopentyl-2-fluoro-4-methoxyphenyl)](3-pyridinylmethylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 857295-21-7 CAPLUS
CN Benzoic acid, 3-[[5-(cyclopentyloxy)-2-fluoro-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 857295-22-8 CAPLUS
CN 3-Pyridinemethanamine, N-[5-(cyclopentyloxy)-2-fluoro-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)





L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:453188 CAPLUS
DOCUMENT NUMBER: 141:23427
TITLE: Preparation of N-oxides of heteroarylmethyl phenyl amines as phosphodiesterase 4 inhibitors
INVENTOR(S): Schumacher, Richard A.; Graham, Elizabeth Doorly; Hopper, Allen T.; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046113	A2	20040603	WO 2003-US36986	20031119
WO 2004046113	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506297	AA	20040603	CA 2003-2506297	20031119
US 2004152902	A1	20040805	US 2003-715819	20031119
BR 2003015705	A	20050906	BR 2003-15705	20031119
EP 1569908	A2	20050907	EP 2003-786857	20031119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2005002976	A	20050818	NO 2005-2976	20050617
PRIORITY APPLN. INFO.: US 2002-42721P P 20021119				
WO 2003-US36986				W 20031119

OTHER SOURCE(S): MARPAT 141:23427
GI

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Nitrogen oxides of I (one of A, B, D = NO and the others are CR6; R1-2 = alkyl; R3 = H, cycloalkyl, etc.; R6 = H, halo, alkyl, alkoxy, CN, OH) and related derivs. are prepared for instance, 4-[(3-cyclopentyloxy-4-methoxyphenyl)amino]pyridine is alkylated with 3-chloromethylpyridine N-oxide (preparation given) (DMF, NaH) to give II. I are inhibitors of PDE4

and useful for the treatment of depression, Alzheimer's disease, etc.
IT 699004-00-7P, N-[3,4-bis(difluoromethoxy)phenyl]-N-[(1-oxo-3-pyridyl)methyl]-4-[2-(tetrahydrofuran-2-yl)-2H-tetrazol-5-yl]aniline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of N-oxides of heteroarylmethyl Ph amines as phosphodiesterase 4 inhibitors)

RN 699004-00-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-[4-[2-(tetrahydro-2H-pyran-2-yl)-2H-tetrazol-5-yl]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 699003-94-6P 699003-95-7P, 4-[N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid
699003-97-9P, 3-[N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699003-98-0P
699003-99-1P 699004-01-8P, 3'-Chloro-3-cyclopentyloxy-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]diphenylamine 699004-02-9P, 3'-Chloro-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]-3-[(tetrahydrofuran-3-yl)oxy]diphenylamine 699004-03-0P 699004-04-1P, 4-Difluoromethoxy-N-[(1-oxo-3-pyridyl)methyl]-3-[(tetrahydrofuran-3-yl)oxy]diphenylamine 699004-05-2P, 3,4-Bis(difluoromethoxy)-N-[(1-oxo-3-pyridyl)methyl]diphenylamine 699004-06-3P
699004-07-4P 699004-08-5P 699004-09-6P, 4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]diphenylamine 699004-10-9P, 3-[N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-11-0P, 3-[N-(4-Methoxy-3-[(tetrahydrofuran-3-yl)oxy]phenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-12-1P
699004-13-2P, 4-[N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-14-3P, 3-[N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-15-4P, 3-[N-(3-[3-(4-Chlorophenyl)propoxy]-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-16-5P, 3-[N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-17-6P, 3-[N-(3-(2-Indanyloxy)-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-18-7P, 3-[N-(3-(2-Methoxyethoxy)-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-19-8P, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-[(1-oxo-3-pyridyl)methyl]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-20-1P, 3-Cyclopentyloxy-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-21-2P, 3-Cyclopentyloxy-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]-3'-(2H-tetrazol-5-yl)diphenylamine 699004-22-3P, (R)-4-Methoxy-N-[(1-oxo-3-pyridyl)methyl]-3-[(tetrahydrofuran-3-yl)oxy]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-23-4P, 3-Cyclopropylmethoxy-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-24-5P, (R)-4-Difluoromethoxy-N-[(1-oxo-3-pyridyl)methyl]-3-[(tetrahydrofuran-3-yl)oxy]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-25-6P, 3-Cyclopentyloxy-4-difluoromethoxy-N-[(1-oxo-3-pyridyl)methyl]-4'-(2H-tetrazol-5-yl)diphenylamine 699004-26-7P, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-[(1-oxo-3-pyridyl)methyl]-3'-(2H-tetrazol-5-yl)diphenylamine 699004-27-8P, 3,4-Bis(difluoromethoxy)-N-[(1-

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 oxo-3-pyridyl)methyl]-4'-[(2H-tetrazol-5-yl)diphenylamine
 699004-32-5P, 3-Cyclopentyl-3'-[(ethanesulfonyl)amino]-4-
 methoxy-N-[(1-oxo-3-pyridyl)methyl]diphenylamine 699004-33-6P,
 3-Cyclopentyl-4-methoxy-3'-[(propanesulfonyl)amino]-N-[(1-oxo-3-
 pyridyl)methyl]diphenylamine 699004-34-7P, 3-Cyclopentyl-4'-
 [(ethanesulfonyl)amino]-4-methoxy-N-[(1-oxo-3-pyridyl)methyl]diphenylamine
 699004-35-8P, 3-Cyclopentyl-4-methoxy-4'-
 [(propanesulfonyl)amino]-N-[(1-oxo-3-pyridyl)methyl]diphenylamine
 699004-36-9P, 3-Cyclopropyl-4-methoxy-3'-[(ethanesulfonyl)amino]-4-
 methoxy-N-[(1-oxo-3-pyridyl)methyl]diphenylamine 699004-37-0P
 699004-38-1P, 4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-[(1-oxo-3-
 pyridyl)methyl]diphenylamine 699004-39-2P 699004-40-5P
 3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-[(1-oxo-3-
 pyridyl)methyl]diphenylamine 699004-41-6P, 3-Cyclopentyl-4-
 methoxy-4'-[(5-oxopyrrolidinyl)methoxy]-N-[(1-oxo-3-
 pyridyl)methyl]diphenylamine 699004-42-7P, 3-Cyclopentyl-4-
 methoxy-N-3-(aminocarbonyl)phenyl]-N-[(1-oxo-3-pyridyl)methyl]aniline
 699004-43-8P, 3,4-Bis(difluoromethoxy)-N-(3-carboxy-4-
 chlorophenyl)-N-[(1-oxo-3-pyridyl)methyl]aniline 699004-44-9P,
 3,4-Bis(difluoromethoxy)-N-[4-(pyrrol-1-yl)phenyl]-N-[(1-oxo-3-
 pyridyl)methyl]aniline 699004-45-0P 699004-46-1P
 699004-48-3P, 3-Cyclopentyl-4-methoxy-N-(4-carboxy-3-
 chlorophenyl)-N-[(1-oxo-3-pyridyl)methyl]aniline 699004-54-1P
 699004-55-2P 699004-56-3P 699004-57-4P,
 3-[N-(3-Cyclopentyl-4-methoxyphenyl)-N-[(1-oxo-2-
 pyridyl)methyl]amino]benzoic acid 699004-58-5P
 699004-59-6P 699004-60-9P 699004-61-0P
 699004-62-1P 699004-63-2P 699004-64-3P
 699004-65-4P 699004-66-5P, 3-[N-(3-Cyclopentyl-4-
 methoxyphenyl)-N-[(5-fluoro-1-oxo-3-pyridyl)methyl]amino]benzoic acid
 699004-67-6P, 4-[N-(3-Cyclopentyl-4-methoxyphenyl)-N-[(5-fluoro-
 1-oxo-3-pyridyl)methyl]amino]benzoic acid 699004-68-7P
 699004-69-8P, 3-[N-(3-Cyclobutyl-4-methoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699004-70-1P,
 3-[N-(3-Cyclopentyl-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]-
 5-fluorobenzoic acid 699004-71-2P, 3-[N-(3,4-
 Bis(difluoromethoxy)phenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]-5-
 fluorobenzoic acid 699004-72-3P, 4-[N-(3-Cyclobutyl-4-
 methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic acid
 699004-76-7P, 4-[N-(3-Ethoxy-4-methoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699004-81-4P,
 4-[N-(3-Isopropoxy-4-methoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699004-85-8P
 699004-88-1P, N-[3,4-Bis(difluoromethoxy)phenyl]-4-[[[4-
 fluorophenyl)sulfonyl]amino]carbonyl]-N-[(1-oxo-3-pyridyl)methyl]aniline
 699004-91-6P 699004-93-6P 699004-94-9P
 699004-95-0P, 3-[N-(3,4-Dimethoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699004-96-1P,
 3-[N-(3-Ethoxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoic
 acid 699004-97-2P, 3-[N-(3-Isopropoxy-4-methoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699004-98-3P,
 4-[[[3,4-Difluorophenyl)sulfonyl]amino]carbonyl]-N-(3-ethoxy-4-
 methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]aniline 699004-99-4P,
 3-[N-(4-Difluoromethoxy-3-ethoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699005-00-0P,
 4-[N-(4-Difluoromethoxy-3-ethoxyphenyl)-N-[(1-oxo-3-
 pyridyl)methyl]amino]benzoic acid 699005-01-1P,
 3-[N-(4-Difluoromethoxy-3-methoxyphenyl)-N-[(1-oxo-3-

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 pyridyl)methyl]amino]benzoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 [Prepn. of N-oxides of heteroaryl methyl Ph amines as phosphodiesterase
 4 inhibitors]
 RN 699003-94-6 CAPLUS
 CN 3-Pyridinemethanamine,
 N-(3-chlorophenyl)-N-[4-methoxy-3-[(3R)-tetrahydro-
 3-furanyl]oxy]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 699003-95-7 CAPLUS
 CN Benzoic acid, 4-[[3-(cyclopentyl-4-methoxyphenyl)](1-oxido-3-
 pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699003-97-9 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentyl-4-methoxyphenyl)](1-oxido-3-
 pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 699003-98-0 CAPLUS
 CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl]](1-oxido-3-
 pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699003-99-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-[3-(1H-
 tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-01-8 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[3-(cyclopentyl-4-
 methoxyphenyl)]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-02-9 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[(tetrahydro-3-
 furanyl]oxy]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 699004-03-0 CAPLUS
 CN Benzonitrile, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]](1-
 oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 699004-04-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(tetrahydro-3-
 furanyl]oxy]phenyl]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-05-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-06-3 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-07-4 CAPLUS
CN Benzonitrile, 3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 699004-11-0 CAPLUS
CN Benzoic acid, 3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-12-1 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-08-5 CAPLUS
CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-09-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyl)oxy]-4-methoxyphenyl]-N-[4-[(1,1-dimethylethyl)dimethylsilyl]oxyphenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-10-9 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyl)oxy]-4-(difluoromethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)


RN 699004-13-2 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-14-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699004-15-4 CAPLUS
CN Benzoic acid, 3-[[3-(4-chlorophenyl)propoxy]-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-16-5 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopropylmethoxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-17-6 CAPLUS


L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzoic acid, 3-[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699004-18-7 CAPLUS
 CN Benzoic acid, 3-[[4-methoxy-3-(2-methoxyethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-19-8 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-20-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 699004-24-5 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-25-6 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-26-7 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-[3-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 699004-21-2 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-22-3 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-23-4 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 699004-27-8 CAPLUS
 CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-32-5 CAPLUS
 CN Ethanesulfonamide, N-[3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-33-6 CAPLUS
 CN 1-Propanesulfonamide, N-[3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-34-7 CAPLUS
 CN Ethanesulfonamide, N-[4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-35-8 CAPLUS
 CN 1-Propanesulfonamide, N-[4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-36-9 CAPLUS
 CN Ethanesulfonamide, N-[3-[[3-(cyclopropylmethoxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-40-5 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 699004-41-6 CAPLUS
 CN 2-Pyrrolidinone, 1-[[4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 699004-42-7 CAPLUS
 CN Benzamide, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-37-0 CAPLUS
 CN Ethanesulfonamide, N-[3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-38-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-39-2 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 699004-43-8 CAPLUS
 CN Benzoic acid, 5-[[3,4-bis(difluoromethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 699004-44-9 CAPLUS
 CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 699004-45-0 CAPLUS
 CN Benzoic acid, 2-chloro-5-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-46-1 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-48-3 CAPLUS
CN Benzoic acid,
2-chloro-4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-54-1 CAPLUS
CN Benzoic acid, 4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-55-2 CAPLUS
CN Benzoic acid,
N-[(4-fluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-56-3 CAPLUS
CN Benzoic acid,
3-[[5-fluoro-1-oxido-3-pyridinyl)methyl][4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-57-4 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-2-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-58-5 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-59-6 CAPLUS
CN Benzoic acid, N-(ethylsulfonyl)-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 RN 699004-60-9 CAPLUS
 CN Benzamide,
 N-[(2-fluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-
 3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 699004-61-0 CAPLUS
 CN Benzamide,
 N-[(3-chlorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-
 3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 699004-62-1 CAPLUS
 CN Benzoic acid, 5-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-
 oxido-3-pyridinyl)methyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX
 NAME)

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 699004-65-4 CAPLUS
 CN Benzamide, 4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-
 oxido-3-pyridinyl)methyl]amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 699004-66-5 CAPLUS
 CN Benzoic acid,
 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(5-fluoro-1-oxido-3-
 pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699004-67-6 CAPLUS
 CN Benzoic acid,
 4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(5-fluoro-1-oxido-3-


L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

Absolute stereochemistry.



RN 699004-63-2 CAPLUS
 CN Benzoic acid, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-
 furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 699004-64-3 CAPLUS
 CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-
 furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]-N-(methylsulfonyl)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 699004-68-7 CAPLUS
 CN Benzoic acid, 3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-
 furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.




RN 699004-69-8 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-
 pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-70-1 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-
 pyridinyl)methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 699004-71-2 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(di fluoromethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 699004-72-3 CAPLUS
CN Benzoic acid, 4-[[3-(cyclobutyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-76-7 CAPLUS
CN Benzoic acid, 4-[(3-ethoxy-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino)- (9CI) (CA INDEX NAME)




RN 699004-91-6 CAPLUS
CN Benzamide, N-[(2,4-difluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-93-8 CAPLUS
CN Benzamide, N-[(3,4-difluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-81-4 CAPLUS
CN Benzoic acid, 4-[[4-methoxy-3-(1-methylethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-85-8 CAPLUS
CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]-N-[(3,4-difluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 699004-88-1 CAPLUS
CN Benzamide, 4-[[3,4-bis(difluoromethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 699004-94-9 CAPLUS
CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl][(1-oxido-3-pyridinyl)methyl]amino]-N-(ethylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 699004-95-0 CAPLUS
CN Benzoic acid, 3-[(3,4-dimethoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino)- (9CI) (CA INDEX NAME)




RN 699004-96-1 CAPLUS
CN Benzoic acid, 3-[(3-ethoxy-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino)- (9CI) (CA INDEX NAME)





RN 699004-97-2 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-(1-methylethoxy)phenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 699004-98-3 CAPLUS
CN Benzoamide, N-[(3,4-difluorophenyl)sulfonyl]-4-[(3-ethoxy-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino)- (9CI) (CA INDEX NAME)




RN 699004-99-4 CAPLUS
CN Benzoic acid, 3-[[4-(difluoromethoxy)-3-ethoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699005-00-0 CAPLUS
CN Benzoic acid, 4-[[4-(difluoromethoxy)-3-ethoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 699005-01-1 CAPLUS
CN Benzoic acid, 3-[[4-(difluoromethoxy)-3-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)





IT 699003-96-8, tert-Butyl 4-[N-(3-cyclopentyloxy-4-methoxyphenyl)-N-[(1-oxo-3-pyridyl)methyl]amino]benzoate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-oxides of heteroaryl methyl Ph amines as phosphodiesterase 4 inhibitors)
RN 699003-96-8 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl][(1-oxido-3-pyridinyl)methyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2004:80654 CAPLUS
DOCUMENT NUMBER: 140:128150
TITLE: Preparation of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses
INVENTOR(S): Schumacher, Richard A.; Hopper, Allen T.; Tehim, Ashok; Hess, Hans-Jurgen Ernst; Unterbeck, Axel; Kuester, Erik; Brubaker, William Frederick, Jr.;
Dunn, Robert F.
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 199 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009552	A1	20040129	WO 2003-US22543	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492907	AA	20040129	CA 2003-2492907	20030721
US 2005119225	A1	20050602	US 2003-622833	20030721
BR 2003012999	A	20050607	BR 2003-12999	20030721
EP 1539697	A1	20050615	EP 2003-765748	20030721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2005008070	A	20050331	NO 2005-870	20050218
PRIORITY APPLN. INFO.:			US 2002-396725P	P 20020719
			WO 2003-US22543	W 20030721

OTHER SOURCE(S): MARPAT 140:128150
GI



AB PDE4 inhibition (no data) is achieved by novel compds., e.g., ether-functionalized N-substituted aniline and diphenylamine analogs (shown as I; variables defined below; e.g. II). Although the methods of preparation are not claimed, >40 example preps. are included. For example, II

was prepared by arylation of N-[(3-pyridyl)methyl]-3-cyclopentyl-4-methoxyaniline by iodobenzene using NaOtBu, Pd2dba3, and PtBu3 in toluene. In a 'passive avoidance in rats' test, an in vivo test for learning and memory, the amnesic effect of MK-801 is reversed in a statistically significant manner by actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine, ED range = 0.5 to 2.5 mg/kg, i.p.] and N-(3-cyclopentyl-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid, ED range = 0.1 to 2.5 mg/kg, i.p.).


In a 'radial arm maze task in rats' test, an in vivo test for learning and memory, the amnesic effect of MK-801 on working memory is reversed in a statistically significant manner by the administration of actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine, ED = 2.5 mg/kg, i.p.; p<0.01]. For I: R1 is H, alkyl having 1-4 C atoms (un)substituted by ≥ 1 halo; R2 is C1-12 alkyl, C3-10 cycloalkyl, C4-16 cycloalkylalkyl, C6-14 aryl, C6-14 aryl-C1-5-alkyl, a partially unsatd. carbocyclic group having 5-14

C atoms, a C5-10 heterocyclic group, or a heterocycle-alkyl group; R3 is H, C1-8 alkyl, a partially unsatd. carbocycle-alkyl group, C7-19 aryl-C1-5-alkyl, or heteroarylalkyl; R4 is H, C3-10 cycloalkyl, C6-14 aryl, or heteroaryl having 5-10 ring atoms; addnl. details are given in the claims.

IT 460080-73-3P, 3-[(3-Cyclopentyl-4-methoxyphenyl)[(3-pyridyl)methyl]amino]benzoic acid 651022-27-4P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-bromoaniline 651022-32-1P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-methylthioaniline 651022-51-4P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
furanyl]oxy]phenyl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-51-4 CAPLUS
CN 1H-Pyrrole, 1-[[4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-54-7 CAPLUS
CN Benzoic acid, 3-[(3-hydroxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 651022-55-8 CAPLUS


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyridyl)methyl]-4-[(2,5-dimethylpyrrol-1-yl)sulfonyl]aniline 651022-54-7P, 3-[(3-Hydroxy-4-methoxyphenyl)[(3-pyridyl)methyl]amino]benzoic Acid 651022-55-8P, Methyl 3-[(3-Hydroxy-4-methoxyphenyl)[(3-pyridyl)methyl]amino]benzoate 651022-59-2P, Methyl 3-[(3-(3-hydroxycyclopentyl)oxy)-4-methoxyphenyl][(3-pyridyl)methyl]amino]benzoate 651022-64-9P, 4-[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl][(3-pyridyl)methyl]amino]benzoic acid 651022-92-3P, 3,4-Bis(difluoromethoxy)-N-(3-carboxyphenyl)-N-[(4-chloropyridin-3-yl)methyl]aniline 651023-16-4P, 3-Cyclopentyl-4-methoxy-N-(3-carboxy-4-nitrophenyl)-N-[(3-pyridyl)methyl]aniline 651023-96-0P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-(aminosulfonyl)aniline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses)

RN 460080-73-3 CAPLUS
CN Benzoic acid, 3-[(3-(cyclopentyl)oxy)-4-methoxyphenyl][(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-27-4 CAPLUS
CN 3-Pyridinemethanamine, N-(4-bromophenyl)-N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-32-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzoic acid, 3-[(3-hydroxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 651022-59-2 CAPLUS
CN Benzoic acid, 3-[(3-[(3-hydroxycyclopentyl)oxy]-4-methoxyphenyl)(3-pyridinylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 651022-64-9 CAPLUS
CN Benzoic acid, 4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651022-92-3 CAPLUS
CN Benzoic acid, 3-[(3,4-bis(difluoromethoxy)phenyl)[(4-chloro-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-16-4 CAPLUS
CN Benzoic acid, 5-[[[3-(cyclopentylloxy)-4-methoxyphenyl]-(3-pyridyl)methyl]amino]-2-nitro- (9CI) (CA INDEX NAME)



RN 651023-96-0 CAPLUS
CN Benzenesulfonamide, 4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-(3-pyridyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 460080-72-2P, 3-Cyclopentylloxy-4-methoxy-N-[(3-pyridyl)methyl]diphenylamine 460080-75-5P, 2-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 460080-77-7P, 3-Cyclopentylloxy-4-methoxy-N-[(3-pyridyl)methyl]amino-2-nitro- (9CI), 3-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]-6-methylbenzoic acid 651022-65-0P, 4-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(5-fluoro-3-pyridyl)methyl]amino]benzoic acid 651022-67-2P, 3-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]-5-trifluoromethylbenzoic acid 651022-68-3P, 3-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]-6-trifluoromethylbenzoic acid 651022-69-4P, 4-[[[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-70-7P, 3-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(5-fluoro-3-pyridyl)methyl]amino]benzoic acid 651022-71-8P, 4-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(5-fluoro-3-pyridyl)methyl]amino]benzoic acid 651022-72-9P, 3-[[[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-73-0P, 3-[[[3-Cyclobutylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-74-1P, 3-[[[3-Cyclohexylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-75-2P, 3-[[[3-Cycloheptyloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-76-3P, 3-[[[4-Methoxy-3-[(R)-tetrahydrofuran-4-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-77-4P, 3-[[[3-[(Bicyclo[2.2.2]octanyl)oxy]-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-80-9P, 3-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]-5-fluorobenzoic acid 651022-81-0P, 3-[[[3-Cyclopentylloxy-4-difluoromethoxyphenyl]-(3-pyridyl)methyl]amino]-5-fluorobenzoic acid 651022-82-1P, 3-[[[3,4-Bis(difluoromethoxy)phenyl]-(3-pyridyl)methyl]amino]-5-fluorobenzoic acid 651022-83-2P, 4-[[[3-Cyclobutylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-84-3P, 4-[[[3-Cyclohexylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-85-4P, 4-[[[4-Methoxy-3-[(2-pyridyl)ethoxy]phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-86-5P, 4-[[[3,4-Dimethoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-87-6P, 4-[[[3-Ethoxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-88-7P, 4-[[[3-Isopropoxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-89-8P, 3,4-Bis(difluoromethoxy)-N-(3-carboxyphenyl)-N-[(2-chloropyridin-5-yl)methyl]aniline 651022-90-1P, 3,4-Bis(difluoromethoxy)-N-(3-carboxyphenyl)-N-[(2-chloropyridin-3-yl)methyl]aniline 651022-93-4P, 3,4-Bis(difluoromethoxy)-N-(3-carboxy-4-chlorophenyl)-N-[(3-pyridyl)methyl]aniline 651022-94-5P, 3,4-Bis(difluoromethoxy)-N-(3-carboxyphenyl)-N-[(4-methoxypyridin-3-yl)methyl]aniline 651022-95-6P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxyphenyl)-N-[(4-chloropyridin-3-yl)methyl]aniline 651022-96-7P, 3,4-Bis(difluoromethoxy)-N-(3-carboxyphenyl)-N-[(3,5-dichloropyridin-4-yl)methyl]aniline 651022-97-8P, 3-Cyclopentylloxy-4-hydroxy-N-(3-carboxyphenyl)-N-[(3-pyridyl)methyl]aniline 651022-98-9P, 4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy-N-(3-carboxy-4-chlorophenyl)-N-[(3-pyridyl)methyl]aniline 651022-99-0P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxyphenyl)-N-[(3-pyridyl)methyl]aniline 651022-01-7P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxyphenyl)-N-[(4-pyridyl)methyl]aniline 651023-01-7P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxyphenyl)-N-[(4-pyridyl)methyl]aniline 651023-02-8P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-[(3-pyridyl)methyl]aniline

methoxy-N-[(3-pyridyl)methyl]-4'-[(2H-tetrazol-5-yl)diphenylamine 460080-91-5P, 3-Cyclopentylloxy-4-methoxy-N-[(4-methyl-1-piperazinyl)methyl]diphenylamine 460080-92-6P, 460080-93-7P, 3'-Aminoethyl-3-cyclopentylloxy-4-methoxy-N-[(3-pyridyl)methyl]diphenylamine 460080-94-8P, 3-Hydroxy-4-methoxy-N-[(3-pyridyl)methyl]diphenylamine 460080-96-0P, 3-Cyclopentylloxy-4-methoxy-3'-[2-(1-piperidinyl)ethoxy]-N-[(3-pyridyl)methyl]diphenylamine 460080-98-2P, 4'-(2-Aminoethoxy)-3-cyclopentylloxy-4-methoxy-N-[(3-pyridyl)methyl]diphenylamine 460082-01-3P, 4-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-26-5P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(N-piperidinyl)methyl]aniline 651022-29-6P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(morpholinyl)methyl]aniline 651022-30-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(N,N-diethylamino)methyl]aniline 651022-31-0P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-methylthioaniline 651022-33-2P, 3,4-Bis(difluoromethoxy)-N-[(4-pyridyl)methyl]aniline 651022-34-3P, 3-Cyclopentylloxy-4-methoxy-N-[(3-[(1,1-dimethylethoxy)carbonyl]phenyl)-N-[(3-pyridyl)methyl]aniline 651022-37-6P, 3-Cyclopentylloxy-4-methoxy-N-[(4-bis(2,4-dimethoxybenzyl)amino)sulfonyl]phenyl]-N-[(3-pyridyl)methyl]aniline 651022-38-7P, N-[(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-39-8P, N-[(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-[(4-morpholinyl)sulfonyl]aniline 651022-40-1P, N-[(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-41-2P, N-[(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[(4-morpholinyl)sulfonyl]aniline 651022-42-3P, N-[(4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-43-4P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-44-5P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-morpholinyl)sulfonyl]aniline 651022-45-6P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-[(4-morpholinyl)sulfonyl]aniline 651022-46-7P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-47-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-cyclohexylpiperazin-1-yl)sulfonyl]aniline 651022-48-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-methylpiperazin-1-yl)sulfonyl]aniline 651022-50-3P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl]aniline 651022-52-5P, 3-[[[3-(2-Hydroxycyclopentylloxy)-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-57-0P, Methyl 3-[[[3-(2-Hydroxycyclopentylloxy)-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoate 651022-58-1P, 3-[[[3-(3-Hydroxycyclopentylloxy)-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651022-60-5P, 4-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(3-pyridyl)methyl]amino]-2-chlorobenzoic acid 651022-61-6P, 4-[[[3,4-Bis(difluoromethoxy)phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-03-9P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxy-3-methylphenyl)-N-[(3-pyridyl)methyl]aniline 651023-04-0P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxy-3-fluorophenyl)-N-[(3-pyridyl)methyl]aniline 651023-05-1P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxy-4-chlorophenyl)-N-[(3-pyridyl)methyl]aniline 651023-06-2P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxy-4-fluorophenyl)-N-[(3-pyridyl)methyl]aniline 651023-07-3P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxyphenyl)-N-[(3,5-dichloropyridin-4-yl)methyl]aniline 651023-08-4P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxyphenyl)-N-[(3,5-dichloropyridin-4-yl)methyl]aniline 651023-09-5P, 3-Cyclopentylloxy-4-methoxy-N-(4-carboxyphenyl)-N-[(3-chloropyridin-4-yl)methyl]aniline 651023-10-6P, 4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy-N-(4-carboxyphenyl)-N-[(3,5-dichloropyridin-4-yl)methyl]aniline 651023-12-8P, 4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy-N-(3-carboxyphenyl)-N-[(3,5-dichloropyridin-4-yl)methyl]aniline 651023-14-2P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]aniline 651023-15-3P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxy-4-methylphenyl)-N-[(3-pyridyl)methyl]aniline 651023-17-5P, 3-[[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-(5-chloro-3-pyridyl)methyl]amino]benzoic acid 651023-20-0P, 4-[[[3-Cyclopentylloxy-4-difluoromethoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-21-1P, 3-[[[3,4-Dimethoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-23-3P, 3-[[[3-Ethoxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-24-4P, 3-[[[4-Methoxy-3-propoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-25-5P, 3-[[[4-Methoxy-3-[(propan-2-yl)oxy]phenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-26-6P, 3-[[[3-(2-Cyclopropylethoxy)-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-27-7P, 3-[[[3-Cyclobutylmethoxy-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoic acid 651023-31-3P, tert-Butyl N-(3-cyclopentylloxy-4-methoxyphenyl)-N-[2-(3-pyridyl)ethyl]-3-amino benzoate 651023-33-5P, 3-[[[3-Cyclopentylloxy-4-methoxyphenyl]-(2-pyridin-3-yl)ethyl]amino]benzoic acid 651023-34-6P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-chloro-4-(2H-tetrazol-5-yl)aniline 651023-35-7P, N-[(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-chloro-4-(2H-tetrazol-5-yl)aniline 651023-36-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(4-(3,5-dichloropyridinyl)methyl)-4-(2H-tetrazol-5-yl)aniline 651023-37-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-piperidinyl)sulfonyl]aniline 651023-38-0P, 3-Cyclopentylloxy-4-hydroxy-N-[(3-[(1,1-dimethylethoxy)carbonyl]phenyl)-N-[(3-pyridyl)methyl]aniline 651023-39-1P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(4-morpholinyl)sulfonyl]aniline 651023-40-2P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-(4-methyl-1-piperazinyl)aniline 651023-41-5P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[(1-piperazinyl)sulfonyl]aniline 651023-42-6P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-(N,N-diethylamino)aniline 651023-43-7P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-(methanesulfonyl)aniline 651023-44-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-methylsulfonyl aniline 651023-45-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[methylsulfonyl]amino]carbonyl]an

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
iline 651023-46-0P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-[[[methylsulfonyl]amino]carbonyl]aniline 651023-47-1P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-[[[2-methylphenyl]sulfonyl]amino]carbonyl]aniline 651023-48-2P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-3-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-49-3P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-50-6P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[methylsulfonyl]amino]carbonyl]aniline 651023-51-7P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-52-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3,5-dichloropyridin-4-yl)methyl]-4-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-53-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3,5-dichloropyridin-4-yl)methyl]-4-[[[methylsulfonyl]amino]carbonyl]aniline 651023-54-0P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[ethylsulfonyl]amino]carbonyl]aniline 651023-55-1P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[2-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-56-2P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[4-methoxyphenyl]sulfonyl]amino]carbonyl]aniline 651023-57-3P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-chlorophenyl]sulfonyl]amino]carbonyl]aniline 651023-58-4P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[methylsulfonyl]amino]carbonyl]aniline 651023-59-5P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-60-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-61-9P, N-(3-Cyclopentylloxy-4-methoxyphenyl)-N-[(5-fluoro-3-pyridyl)methyl]-3-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-62-0P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-[[[methylsulfonyl]amino]carbonyl]aniline 651023-63-1P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-[[[phenylsulfonyl]amino]carbonyl]aniline 651023-64-2P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-chlorophenyl]sulfonyl]amino]carbonyl]aniline 651023-65-3P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[2-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-66-4P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[2,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-67-5P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-68-6P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[1,1-dimethylethyl]sulfonyl]amino]carbonyl]aniline 651023-69-7P,


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
o[sulfonyl]aniline 651023-99-3P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]carbonyl]amino]sulfonyl]aniline 651024-00-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[1-ethyl-5-methylpyrazol-4-yl]carbonyl]amino]sulfonyl]aniline 651024-01-0P
N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-hydroxymethyl]aniline 651024-02-1P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-3-hydroxymethyl]aniline 651024-03-2P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-hydroxymethyl]aniline 651024-04-3P, 3-Cyclopentylloxy-4-methoxy-N-(3-amino)carbonyl]phenyl]-N-[(3-pyridyl)methyl]aniline 651024-05-4P, 3-Cyclopentylloxy-4-methoxy-N-[3-[(methylamino)carbonyl]phenyl]-N-[(3-pyridyl)methyl]aniline 651024-06-5P, 3-Cyclopentylloxy-4-methoxy-N-[3-[(2-hydroxyethyl)amino]carbonyl]phenyl]-N-[(3-pyridyl)methyl]aniline 651024-07-6P, 3-Cyclopentylloxy-4-methoxy-N-phenyl]-N-[(2-ethoxypyridin-3-yl)methyl]aniline 651024-09-8P, 3-Cyclopentylloxy-4-methoxy-N-(4-amino-3-carboxyphenyl)-N-[(3-pyridyl)methyl]aniline 651024-10-1P, 3-Cyclopentylloxy-4-methoxy-N-(4-acetamido-3-carboxyphenyl)-N-[(3-pyridyl)methyl]aniline 651024-11-2P, 3-Cyclopentylloxy-4-methoxy-N-phenyl]-N-[(3-chloropyridin-4-yl)methyl]aniline 651024-12-3P, 3-Cyclopentylloxy-4-methoxy-N-(3-carboxy-4-trifluoromethylphenyl)-N-[(3-pyridyl)methyl]aniline 651024-13-4P, Methyl 3-[(3-cyclopentylloxy-4-methoxyphenyl)](3-pyridyl)methyl]amino]benzoate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses)
RN 460080-72-2 CAPLUS
CN 3-Pyridinemethanamine, N-(3-(cyclopentylloxy)-4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 460080-75-5 CAPLUS
CN Benzoic acid, 2-[(3-(cyclopentylloxy)-4-methoxyphenyl)](3-pyridinylmethyl)amino- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[5-chloro-2-thienyl]sulfonyl]amino]carbonyl]aniline 651023-70-0P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[2-thienyl]sulfonyl]amino]carbonyl]aniline 651023-71-1P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-cyanophenyl]sulfonyl]amino]carbonyl]aniline 651023-72-2P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-73-3P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[2-thienyl]sulfonyl]amino]carbonyl]aniline 651023-74-4P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-75-5P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-cyanophenyl]sulfonyl]amino]carbonyl]aniline 651023-77-7P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-78-8P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[[[2,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-79-9P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[3,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-80-2P, N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-chlorophenyl]sulfonyl]amino]carbonyl]aniline 651023-82-4P, N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-83-5P, N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-84-6P, N-[4-Difluoromethoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[ethylsulfonyl]amino]carbonyl]aniline 651023-85-7P, N-(3-Cyclopentylloxy-4-difluoromethoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-cyanophenyl]sulfonyl]amino]carbonyl]aniline 651023-86-8P, N-(3-Cyclopentylloxy-4-difluoromethoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-88-0P, N-(3-Cyclopentylloxy-4-difluoromethoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-89-1P, N-(3-Cyclopentylloxy-4-difluoromethoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-chlorophenyl]sulfonyl]amino]carbonyl]aniline 651023-90-4P, N-(3-Ethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[2,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-91-5P, N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[ethylsulfonyl]amino]carbonyl]aniline 651023-92-6P, N-(3-Ethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[4-fluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-93-7P, N-(3-Ethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3-chlorophenyl]sulfonyl]amino]carbonyl]aniline 651023-94-8P, N-(3-Ethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[3,4-difluorophenyl]sulfonyl]amino]carbonyl]aniline 651023-95-9P, N-(3-Ethoxy-4-methoxyphenyl)-N-[(3-pyridyl)methyl]-4-[[[2-thienyl]sulfonyl]amino]carbonyl]aniline 651023-97-1P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[methylcarbonyl]amino]sulfonyl]aniline 651023-98-2P, N-[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl]-N-[(3-pyridyl)methyl]-4-[[[cyclopentyl]methyl]carbonyl]amin


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 460080-77-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460080-85-7 CAPLUS
CN Benamide, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 460080-86-8 CAPLUS
CN Methanesulfonamide, N-[4-[[3-(cyclopentylloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 460080-88-0 CAPLUS
CN Benzenemethanol, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460080-89-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460080-91-5 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

RN 460080-98-2 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(2-aminoethoxy)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460082-01-3 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-28-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651022-29-6 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460080-93-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(aminomethyl)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460080-94-8 CAPLUS
CN Phenol, 2-methoxy-5-(phenyl(3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)



RN 460080-96-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.




RN 651022-30-9 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[(diethylamino)methyl]phenyl]-N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651022-31-0 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651022-33-2 CAPLUS

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN 3-Pyridinemethanamine,
N-[3,4-bis(difluoromethoxy)phenyl]-N-[4-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 651022-34-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651022-37-6 CAPLUS
CN Benzenesulfonamide, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N,N-bis[(2,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651022-42-3 CAPLUS
CN Piperazine, 1-[[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651022-43-4 CAPLUS
CN Piperazine, 1-[[4-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651022-44-5 CAPLUS
CN Morpholine, 4-[[4-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 651022-38-7 CAPLUS
CN Piperazine, 1-[[3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 651022-39-8 CAPLUS
CN Morpholine, 4-[[3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 651022-40-1 CAPLUS
CN Piperazine, 1-[[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 651022-41-2 CAPLUS
CN Morpholine, 4-[[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.




RN 651022-45-6 CAPLUS
CN Morpholine, 4-[[3-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-46-7 CAPLUS
CN Piperazine, 1-ethyl-4-[[4-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-47-8 CAPLUS
CN Piperazine, 1-cyclohexyl-4-[[4-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-48-9 CAPLUS
CN Piperazine,
1-[[4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-
pyridinylmethyl)amino]phenyl]sulfonyl]-3,5-dimethyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 651022-49-0 CAPLUS
CN Piperazine,
1-[[4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-
pyridinylmethyl)amino]phenyl]sulfonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 651022-50-3 CAPLUS
CN Piperazine, 1-(4-fluorophenyl)-4-[[4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-
furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.




RN 651022-52-5 CAPLUS
CN Benzoic acid, 3-[[3-[[2-hydroxycyclopentyl]oxy]-4-methoxyphenyl](3-
pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)



RN 651022-57-0 CAPLUS
CN Benzoic acid, 3-[[3-[[2-hydroxycyclopentyl]oxy]-4-methoxyphenyl](3-
pyridinylmethyl)amino)-, methyl ester (9CI) (CA INDEX NAME)




RN 651022-58-1 CAPLUS
CN Benzoic acid, 3-[[3-[[3-hydroxycyclopentyl]oxy]-4-methoxyphenyl](3-
pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)




RN 651022-60-5 CAPLUS
CN Benzoic acid, 2-chloro-4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-
furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-61-6 CAPLUS
CN Benzoic acid,
4-[[3,4-bis(di fluoromethoxy)phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)




RN 651022-63-8 CAPLUS
CN Benzoic acid, 5-[[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-
pyridinylmethyl)amino)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-65-0 CAPLUS
CN Benzoic acid, 4-[[5-fluoro-3-pyridinyl]methyl][4-methoxy-3-[[[(3R)-
tetrahydro-3-furanyl]oxy]phenyl]amino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 651022-67-2 CAPLUS
 CN Benzoic acid, 3-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651022-68-3 CAPLUS
 CN Benzoic acid, 5-[[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651022-69-4 CAPLUS
 CN Benzoic acid, 4-[[4-(difluoromethoxy)-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651022-70-7 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl]](5-fluoro-3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-71-8 CAPLUS
 CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl]](5-fluoro-3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-72-9 CAPLUS
 CN Benzoic acid, 3-[[4-(difluoromethoxy)-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651022-73-0 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclobutyloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-74-1 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclohexyloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-75-2 CAPLUS
 CN Benzoic acid, 3-[[3-(cycloheptyloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651022-76-3 CAPLUS
 CN Benzoic acid, 3-[[4-methoxy-3-[[3-(3R)-tetrahydro-2H-pyran-4-yl]oxy]phenyl]](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-77-4 CAPLUS
 CN Benzoic acid, 3-[[3-(bicyclo[2.2.2]oct-1-yloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-80-9 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl]](3-pyridinylmethyl)amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 651022-81-0 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 651022-82-1 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 651022-83-2 CAPLUS
CN Benzoic acid, 4-[[3-(cyclobutyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


RN 651022-87-6 CAPLUS
CN Benzoic acid, 4-[[3-ethoxy-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-88-7 CAPLUS
CN Benzoic acid, 4-[[4-methoxy-3-(1-methylethoxy)phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-89-8 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl](6-chloro-3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-90-1 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl](2-chloro-3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-93-4 CAPLUS




RN 651022-84-3 CAPLUS
CN Benzoic acid, 4-[[3-(cyclohexyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-85-4 CAPLUS
CN Benzoic acid, 4-[[4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-86-5 CAPLUS
CN Benzoic acid, 4-[[3,4-dimethoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-89-5 CAPLUS
CN Benzoic acid, 5-[[3,4-bis(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 651022-94-5 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl](4-methoxy-3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 651022-95-6 CAPLUS
CN Benzoic acid, 4-[[4-chloro-3-pyridinylmethyl](3-(cyclopentyloxy)-4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-96-7 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl](3,5-dichloro-4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651022-97-8 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-hydroxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651022-98-9 CAPLUS
CN Benzoic acid, 2-chloro-5-[[4-methoxy-3-[[3(R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-99-0 CAPLUS


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651023-03-9 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 651023-04-0 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-2-fluoro- (9CI) (CA INDEX NAME)



RN 651023-05-1 CAPLUS
CN Benzoic acid, 2-chloro-5-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benzoic acid, 3-[[3-chloro-4-pyridinyl)methyl][3-(cyclopentyloxy)-4-methoxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-00-6 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[[3(R)-tetrahydro-3-furanyl]oxy]phenyl](4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-01-7 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-02-8 CAPLUS
CN Benzoic acid, 2-chloro-4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651023-06-2 CAPLUS
CN Benzoic acid, 5-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 651023-07-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3,5-dichloro-4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 651023-08-4 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3,5-dichloro-4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-09-5 CAPLUS
CN Benzoic acid, 4-[[3-chloro-4-pyridinyl)methyl][3-(cyclopentyloxy)-4-methoxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-10-8 CAPLUS
CN Benzoic acid, 4-[[3,5-dichloro-4-pyridinyl)methyl][4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-12-0 CAPLUS
CN Benzoic acid, 3-[[3,5-dichloro-4-pyridinyl)methyl][4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-14-2 CAPLUS
CN Benzoic acid, 5-[[3-(cyclopentyloxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 651023-15-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 651023-17-5 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651023-20-0 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-21-1 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-23-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-24-4 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-propoxyphenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)



RN 651023-25-5 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-(1-methylethoxy)phenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-26-6 CAPLUS
CN Benzoic acid, 3-[[3-(2-cyclopropylethoxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-27-7 CAPLUS
CN Benzoic acid, 3-[[3-(cyclobutylmethoxy)-4-methoxyphenyl][3-pyridinylmethyl]amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyridinylmethylamino]- (9CI) (CA INDEX NAME)



RN 651023-31-3 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][2-(3-pyridinyl)ethyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 651023-33-5 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl][2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 651023-34-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-chloro-4-(1H-tetrazol-5-yl)phenyl]-N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651023-35-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-chloro-4-(1H-tetrazol-5-yl)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 651023-36-8 CAPLUS
CN 2-Pyridinemethanamine, 3,5-dichloro-N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-37-9 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(4-piperidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.




RN 651023-38-0 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-hydroxyphenyl][3-(pyridinylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651023-39-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-40-4 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)

Absolute stereochemistry.




RN 651023-41-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-42-6 CAPLUS
CN 1,4-Benzenediamine, N,N-diethyl-N'-[4-methoxy-3-[[3-(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651023-43-7 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651023-44-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 651023-47-1 CAPLUS
CN Benzamide, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 651023-48-2 CAPLUS
CN Benzamide, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 651023-49-3 CAPLUS
CN Benzamide, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 651023-50-6 CAPLUS
CN Benzamide, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 651023-45-9 CAPLUS
CN Benzamide, 4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-46-0 CAPLUS
CN Benzamide, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 651023-51-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-52-8 CAPLUS
CN Benzamide, 4-[[3-(3,5-dichloro-4-pyridinyl)methyl][4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-53-9 CAPLUS
 CN Benzamide, 4-[[[3,5-dichloro-4-pyridinyl)methyl][4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-54-0 CAPLUS
 CN Benzamide, N-(ethylsulfonyl)-4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-55-1 CAPLUS
 CN Benzamide, N-[(2-fluorophenyl)sulfonyl]-4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-56-2 CAPLUS
 CN Benzamide, N-[(4-methoxyphenyl)sulfonyl]-4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-57-3 CAPLUS
 CN Benzamide, N-[(3-chlorophenyl)sulfonyl]-4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-58-4 CAPLUS
 CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-59-5 CAPLUS
 CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-60-8 CAPLUS
 CN Benzamide, 4-[[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 651023-61-9 CAPLUS
CN Benzamide, 3-[[[3-(cyclopentyloxy)-4-methoxyphenyl][(5-fluoro-3-pyridinyl)methyl]amino]-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 651023-62-0 CAPLUS
CN Benzamide, 3-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-63-1 CAPLUS
CN Benzamide, 3-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 651023-66-4 CAPLUS
CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-[(2,4-difluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651023-67-5 CAPLUS
CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-[(3,4-difluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-68-6 CAPLUS
CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-[(1,1-dimethylethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651023-64-2 CAPLUS
CN Benzamide, N-[(3-chlorophenyl)sulfonyl]-4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-65-3 CAPLUS
CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-[(2-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651023-69-7 CAPLUS
CN Benzamide, N-[(5-chloro-2-thienyl)sulfonyl]-4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-70-0 CAPLUS
CN Benzamide, 4-[[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(3-thienylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 651023-71-1 CAPLUS
 CN Benzamide, N-[(3-cyanophenyl)sulfonyl]-4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651023-72-2 CAPLUS
 CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-73-3 CAPLUS
 CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651023-74-4 CAPLUS
 CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)-N-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-75-5 CAPLUS
 CN Benzamide, N-[(3-cyanophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651023-77-7 CAPLUS
 CN Benzamide, N-[(3-fluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651023-78-8 CAPLUS
 CN Benzamide, N-[(2,4-difluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651023-79-9 CAPLUS
 CN Benzamide, N-[(3,4-difluorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651023-80-2 CAPLUS
 CN Benzamide, N-[(3-chlorophenyl)sulfonyl]-4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino)- (9CI) (CA INDEX NAME)




RN 651023-82-4 CAPLUS
 CN Benzamide, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 651023-83-5 CAPLUS
 CN Benzamide, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 651023-86-8 CAPLUS
 CN Benzamide, 4-[[3-(cyclopentylmethoxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 651023-88-0 CAPLUS
 CN Benzamide, 4-[[3-(cyclopentylmethoxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-N-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 651023-84-6 CAPLUS
 CN Benzamide, 4-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]-N-(ethylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651023-85-7 CAPLUS
 CN Benzamide, N-[(3-cyanophenyl)sulfonyl]-4-[[3-(cyclopentylmethoxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-89-1 CAPLUS
 CN Benzamide, N-[(3-chlorophenyl)sulfonyl]-4-[[3-(cyclopentylmethoxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-90-4 CAPLUS
 CN Benzamide, N-[(2,4-difluorophenyl)sulfonyl]-4-[[3-(ethoxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-91-5 CAPLUS
CN Benzamide, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(ethylsulfonyl)- (9CI) (CA INDEX NAME)




RN 651023-92-6 CAPLUS
CN Benzamide, 4-[[3-ethoxy-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-[[4-fluorophenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 651023-93-7 CAPLUS
CN Benzamide, N-[(3-chlorophenyl)sulfonyl]-4-[(3-ethoxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 651023-94-8 CAPLUS
CN Benzamide, N-[(3,4-difluorophenyl)sulfonyl]-4-[(3-ethoxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651023-95-9 CAPLUS
CN Benzamide, 4-[[3-ethoxy-4-methoxyphenyl](3-pyridinylmethyl)amino]-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 651023-97-1 CAPLUS
CN Acetamide, N-[[4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyloxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-98-2 CAPLUS
CN Acetamide, N-cyclopentyl-N-[[4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyloxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651023-99-3 CAPLUS
CN Benzamide, 4-fluoro-N-[[4-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyloxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651024-00-9 CAPLUS
CN 1H-Pyrazole-4-carboxamide,
1-ethyl-N-[[4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-
furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]sulfonyl]-5-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651024-01-0 CAPLUS
CN Benzenemethanol,
3-[[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651024-05-4 CAPLUS
CN Benzamide, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 651024-06-5 CAPLUS
CN Benzamide, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 651024-07-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-2-ethoxy-
phenyl- (9CI) (CA INDEX NAME)




RN 651024-02-1 CAPLUS
CN Benzenemethanol, 3-[[4-(difluoromethoxy)-3-[[[(3R)-tetrahydro-3-
furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651024-03-2 CAPLUS
CN Benzenemethanol,
4-[[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651024-04-3 CAPLUS


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651024-09-8 CAPLUS
CN Benzoic acid, 2-amino-5-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651024-10-1 CAPLUS
CN Benzoic acid, 2-(acetamido)-5-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 651024-11-2 CAPLUS
CN 4-Pyridinemethanamine, 3-chloro-N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-
phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 651024-12-3 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 651024-13-4 CAPLUS
 CN Benzoic acid, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




IT 460080-74-4, Ethyl 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]benzoate 460080-76-6, tert-Butyl 2-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]benzoate 460080-78-8, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-[(3-pyridinylmethyl)-4'-[2-(tetrahydropyran-2-yl)-2H-tetrazol-5-yl]diphenylamine 460080-87-9, 4'-Amino-3-cyclopentylloxy-4-methoxy-N-[(3-pyridinylmethyl)diphenylamine 460080-90-4,

3-[[3-(Cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]benzonitrile 460080-95-9, 3-(tert-Butyldimethylsiloxy)-N-[(3-pyridinylmethyl)-4-methoxydiphenylamine 460080-97-1, 3'-(2-Bromoethoxy)-3-cyclopentylloxy-4-methoxy-N-[(3-pyridinylmethyl)diphenylamine 460080-99-3, N-[(3-Pyridinylmethyl)-3'-(2-(2-phthalimido)ethoxy)-3-cyclopentylloxy-4-methoxydiphenylamine 460082-00-2, 3-[[4-Methoxy-3-[(R)-tetrahydrofuran-3-yl]oxy]phenyl](3-pyridinylmethyl)amino]benzoic acid 651022-62-7, tert-Butyl 4-[[3,4-bis(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]benzoate 651024-08-7, 3-Cyclopentylloxy-4-methoxy-N-phenyl-N-[(2-chloropyridin-3-yl)methyl]aniline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses)
 RN 460080-74-4 CAPLUS


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 460080-90-4 CAPLUS
 CN Benzonitrile, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460080-95-9 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-[[1,1-dimethylethyl]dimethylsilyloxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460080-97-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(2-bromoethoxy)phenyl]-N-[3-(cyclopentylloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzoic acid, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 460080-76-6 CAPLUS
 CN Benzoic acid, 2-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 460080-78-8 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-[4-[2-(tetrahydro-2H-pyran-2-yl)-2H-tetrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 460080-87-9 CAPLUS
 CN 1,4-Benzenediamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 460080-99-3 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[2-[3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 460082-00-2 CAPLUS
 CN Benzoic acid, 3-[[4-methoxy-3-[[3-(R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651022-62-7 CAPLUS
 CN Benzoic acid, 4-[[3,4-bis(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651024-08-7 CAPLUS
 CN 3-Pyridinemethanamine, 2-chloro-N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



IT 651023-29-9P, Methyl 3-[[3-[(tert-butyl dimethylsilyl)oxy]cyclopentyl]oxy]-4-methoxyphenyl]-(3-pyridyl)methyl]amino]benzoate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses)

RN 651023-29-9 CAPLUS

CN Benzoic acid,
 3-[[3-[[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]oxy]-4-methoxyphenyl]-(3-pyridyl)methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:57887 CAPLUS
 DOCUMENT NUMBER: 138:122459
 TITLE: Preparation of 3-anilino-2-cycloalkenones for treatment of allergic eye diseases
 INVENTOR(S): Ina, Shinji; Takahama, Akane
 PATENT ASSIGNER(S): Nikken Chemicals Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006000	A1	20030123	WO 2002-JP6912	20020708
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2003089637	A2	20030328	JP 2002-198758	20020708
EP 1410795	A1	20040421	EP 2002-743854	20020708
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
CN 1525854	A	20040901	CN 2002-813746	20020708
US 2004220227	A1	20041104	US 2004-482976	20040105
PRIORITY APPLN. INFO.:			JP 2001-210239	A 20010711
			WO 2002-JP6912	W 20020708

OTHER SOURCE(S): MARPAT 138:122459
 GI



AB The title compds. I [wherein R1 = (un)substituted (cyclo)alkyl, bicycloalkyl, 3-tetrahydrofuryl, or indanyl; R2 = alkyl; R3 = H, (un)substituted (cyclo)alkyl, or acyl; R4 = H, halo, (un)substituted alkyl, or aminomethyl; R5, R6, R7, and R8 = independently H,


L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

(un)substituted alkyl, or Ph; X = (CR1R1R2)n; R11 and R12 = independently H, (un)substituted alkyl, or Ph; n = 0-2; with provisos] and stereoisomers, optical isomers, pharmaceutically acceptable salts, hydrates, or solvates thereof are prepd. for the treatment of allergic


eye diseases. For example, (+)-II was isolated from its racemate by HPLC. (+)-II showed inhibition ratio of 97% against allergic conjunctivitis in rat. Formulations contg. I as an active ingredient are also described.

IT 205067-29-4P 229310-57-OP 229310-72-9P
 229310-79-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of anilino-cycloalkenones for treatment of allergic eye diseases)

RN 205067-29-4 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyl)oxy]-4-methoxyphenyl]-(4-pyridyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 229310-57-0 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyl)oxy]-4-methoxyphenyl]-(3-pyridyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 229310-72-9 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl]-(4-pyridyl)methyl]amino]- (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 229310-79-6 CAPLUS
 CN 2-Cyclohexen-1-one, 3-[[3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]oxy]-4-methoxyphenyl]-(4-pyridyl)methyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074726	A2	20020926	WO 2002-US1508	20020122
WO 2002074726	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2435847	AA	20020926	CA 2002-2435847	20020122
US 2002151566	A1	20021017	US 2002-51309	20020122
US 6699890	B2	20040302		
EP 1353907	A2	20031022	EP 2002-731078	20020122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300347	A	20031215	EE 2003-347	20020122
CN 1498211	A	20040519	CN 2002-807010	20020122
JP 200507365	T2	20050517	JP 2002-573735	20020122
US 2003149052	A1	20030807	US 2003-361634	20030211
BG 108003	A	20040930	BG 2003-108003	20030718
NO 200303288	A	20030922	NO 2003-3288	20030721
ZA 2003005623	A	20041117	ZA 2003-5623	20030721
US 2004230072	A1	20041118	US 2004-754600	20040112
PRIORITY APPLN. INFO.:			US 2001-262651P	P 20010122
			US 2001-267196P	P 20010208
			US 2001-306140P	P 20010719
			US 2000-257196P	P 20001222
			US 2002-51309	A3 20020122
			US 2002-51390	A3 20020122
			WO 2002-US1508	W 20020122


OTHER SOURCE(S): MARPAT 137:247488




RN 460080-90-4 CAPLUS
CN Benzonitrile, 3-[[[3-(cyclopentylmethoxy)-4-methoxyphenyl]-N-(3-pyridinylmethyl)amino]-9CI] (CA INDEX NAME)



RN 460080-95-9 CAPLUS
CN 3-Pyridinemethanamine, N-[3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 460080-97-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(2-bromoethoxy)phenyl]-N-(3-(cyclopentylmethoxy)-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



AB Phosphodiesterase 4 (PDE4) inhibition is achieved by novel compds., 4-R10-3-R20C6H3NR3R4 (1, e.g., N-substituted aniline and diphenylamine analogs; e.g. 3-cyclopentylmethoxy-4'-ethyl-4-methoxy-N-(3-pyridinylmethyl)diphenylamine). In 1, R1 is C1-4 alkyl unsubstituted or substituted one or more times by halogen. R2 is C1-12 alkyl, wherein optionally one or more -CH2CH2- groups is replaced in each case by

-CH:CH-

or -C.tpbond.C-, C3-10 cycloalkyl, C4-16 cycloalkylalkyl, C6-14 aryl, arylalkyl with C6-14 aryl and C1-5 alkyl, a partially unsatd. C5-14 carbocyclic group, a C5-10 heterocyclic group, which is saturated,

partially

saturated or unsatd., in which at least 1 ring atom is a N, O or S atom,

or a

heterocycloalkyl group with a C5-10 heterocyclic portion that is

saturated,

partially saturated or unsatd., in which at least 1 ring atom is a N, O

or S

atom, and a C1-5 alkyl portion. R3 is H, C1-8 (preferably C1-4) alkyl, a partially unsatd. carbocycle-alkyl group with a C5-14 carbocyclic portion and a C1-5 alkyl portion, C7-19 arylalkyl with C6-14 aryl and C1-5 alkyl, or heteroarylalkyl with C5-10 heteroaryl having at least 1 ring atom N, O or S atom and with C1-5 alkyl. R4 is H, C6-14 aryl or heteroaryl having

5

to 10 ring atoms in which at least 1 ring atom is a heteroatom. Addnl. restrictions on the values of R1-R4 are given in the claims. The amnesic effect of MK-801 on working memory in rats (radial arm maze task) is reversed in a statistically significant manner by the administration of actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine, ED = 2.5 mg/kg, i.p.; p<0.01]. The amnesic effect of MK-801 on rats in a passive avoidance experiment is reversed in a statistically significant manner by actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine, ED range = 0.5 to 2.5 mg/kg, i.p.; and N-(3-cyclopentylmethoxy-4-methoxyphenyl)-N-(3-pyridinylmethyl)-3-aminobenzoic acid, ED range = 0.1 to 2.5 mg/kg, i.p.]. Although the methods of preparation are not claimed, approx.20 example preps.

are included and hundreds of compds. are listed in the claims.

IT

460080-73-3P, N-(3-Cyclopentylmethoxy-4-methoxyphenyl)-N-(3-pyridinylmethyl)-3-aminobenzoic acid 460080-90-4P, 460080-95-9P, 3-(tert-Butyldimethylsilyloxy)-N-(3-pyridinylmethyl)-4-methoxydiphenylamine 460080-97-1P, 3'-(2-Bromoethoxy)-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Intermediate; preparation of C-organooxy- and N-substituted aniline

and

diphenylamine analogs as phosphodiesterase 4 inhibitors useful for enhancing cognition)

RN

460080-73-3 CAPLUS
CN Benzoic acid, 3-[[[3-(cyclopentylmethoxy)-4-methoxyphenyl]-N-(3-pyridinylmethyl)amino]-9CI] (CA INDEX NAME)

IT

460080-72-2P, 3-Cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460080-75-5P, N-(3-Cyclopentylmethoxy-4-methoxyphenyl)-N-(3-pyridinylmethyl)-2-aminobenzoic acid 460080-77-7P, 3-Cyclopentylmethoxy-4-difluoromethoxy-N-(3-pyridinylmethyl)-4'-(2H-tetrazol-5-yl)diphenylamine 460080-85-7P, 460080-86-8P, 3-Cyclopentylmethoxy-4'-methanesulfonylamino-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460080-88-0P, 3-Cyclopentylmethoxy-4-methoxy-3'-hydroxymethyl-N-(3-pyridinylmethyl)diphenylamine 460080-89-1P, 3-Cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)-4'-(2H-tetrazol-5-yl)diphenylamine 460080-91-5P, 3-Cyclopentylmethoxy-4-methoxy-4'-(4-methyl-1-piperazinylmethyl)-N-(3-pyridinylmethyl)diphenylamine 460080-93-7P, 3'-Aminomethyl-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460080-94-8P, 3-Hydroxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460080-96-0P, 3-Cyclopentylmethoxy-4-methoxy-3'-(2-(1-piperidinyl)ethoxy)-N-(3-pyridinylmethyl)diphenylamine 460080-98-2P, 4'-(2-Aminoethoxy)-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-00-9P, 3-Cyclopentylmethoxy-4'-ethyl-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-01-0P, 3-Cyclopentylmethoxy-3',4-dimethoxy-N-(3-pyridinylmethyl)diphenylamine 460081-02-1P, 3-Cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)-3'-trifluoromethylidiphenylamine 460081-03-2P, 3-Cyclopentylmethoxy-3'-fluoro-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-04-3P, 3-Cyclopentylmethoxy-4'-fluoro-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-05-4P, 3-Cyclopentylmethoxy-4-methoxy-3'-phenyl-N-(3-pyridinylmethyl)diphenylamine 460081-06-5P, 4'-Cyano-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-07-6P, 3-Cyclopentylmethoxy-4-methoxy-3'-nitro-N-(3-pyridinylmethyl)diphenylamine 460081-08-7P, 4'-Chloro-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)-3'-trifluoromethylidiphenylamine 460081-09-8P, 4-Methoxy-3'-methyl-N-(3-pyridinylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine 460081-10-1P, 3-Cyclopentylmethoxy-4-difluoromethoxy-N-(3-pyridinylmethyl)diphenylamine 460081-13-4P, 3'-Benzylsulfonylamino-3-cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-14-5P, 3-[[3-(4-Chlorophenyl)prop-1-yloxy]-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-15-6P, 4-Methoxy-3-[[3-(4-methoxyphenyl)prop-1-yl]oxy]-N-(3-pyridinylmethyl)diphenylamine 460081-16-7P, 4-Methoxy-3-[[3-(2-pyridinyl)prop-1-yl]oxy]-N-(3-pyridinylmethyl)diphenylamine 460081-17-8P, 3-Cyclopentylmethoxy-4'-(2-methoxyethoxy)-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-19-0P, 3-Cyclopentylmethoxy-4-methoxy-N-(3-pyridinylmethyl)-4'-(3R)-tetrahydrofuran-2-ylidiphenylamine 460081-21-4P, 3-Cyclopentylmethoxy-4-methoxy-4'-(1-methylpiperidin-4-yloxy)-N-(3-pyridinylmethyl)diphenylamine 460081-23-6P, 3-Cyclopentylmethoxy-4-methoxy-4'-(1-methylpyrrolidin-3-yloxy)-N-(3-pyridinylmethyl)diphenylamine 460081-25-8P, 3-Cyclopentylmethoxy-4-methoxy-4'-(2-(1-pyrrolidinyl)ethoxy)diphenylamine 460081-27-0P, 3-Cyclopentylmethoxy-4-methoxy-4'-[[6-methyl-2-pyridyl]methoxy]-N-(3-pyridinylmethyl)diphenylamine 460081-29-2P, 3-Cyclopentylmethoxy-4-methoxy-4'-[[1-methyl-2-piperidinyl]methoxy]-N-(3-pyridinylmethyl)diphenylamine 460081-30-5P, 3-Cyclopentylmethoxy-3'-(2-(1-imidazolyl)ethoxy)-4-methoxy-N-(3-pyridinylmethyl)diphenylamine 460081-32-7P, 3-Cyclopentylmethoxy-4-methoxy-4'-[[3-(2-methylpiperazin-4-yl)propoxy]-N-(3-pyridinylmethyl)diphenylamine 460081-34-9P,

3-Cyclopentylmethoxy-4-methoxy-4'-[[3-(2-(morpholin-4-yl)ethyl)amino]propoxy]-N-(3-pyridinylmethyl)diphenylamine 460081-36-1P,

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 3-(2-(4-Chlorophenoxy)ethoxy)-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-38-3P, 3-(2-(4-Chlorophenylamino)ethoxy)-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-39-4P, 3-Cyclopentyl-4'-[2-
 (methanesulfonylamino)ethoxy]-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-40-7P, 4'-[2-(Butanesulfonylamino)ethoxy]-3-cyclopentyl-4-
 methoxy-N-(3-pyridylmethyl)diphenylamine 460081-41-8P, 3-
 Cyclopentyl-4-methoxy-3'-methyl-N-(3-pyridylmethyl)diphenylamine
 460081-43-0P, 3-Cyclopentyl-4-methoxy-4'-methyl-N-(3-
 pyridylmethyl)diphenylamine 460081-45-2P, 3-Cyclopentyl-4-
 methoxy-4'-nitro-N-(3-pyridylmethyl)diphenylamine 460081-47-4P,

3-Cyclopentyl-3',4'-dichloro-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-48-5P, 3'-Chloro-3-cyclopentyl-4'-fluoro-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-49-6P, 3-Cyclopentyl-4-
 (2,6-dichloro-4-pyridylmethyl)-4-methoxydiphenylamine 460081-50-9P,
 4-Methoxy-4'-methyl-N-(3-pyridylmethyl)-3-(3-
 tetrahydrofuryloxy)diphenylamine 460081-51-0P,
 4,4'-Dimethoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine
 460081-52-1P, 3-Indanyloxy-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-53-2P, N-[4-Methoxy-3-(2-
 pyridyl)ethoxy]phenyl-N-(3-pyridylmethyl)-3-aminobenzoic acid
 460081-58-7P, 3-Cyclopentyl-4-methoxy-3'-(4-methylpiperazin-1-
 ylcarbonyl)-N-(3-pyridylmethyl)diphenylamine 460081-59-8P,
 3-Cyclopentyl-4-difluoromethoxy-4'-(4-methylpiperazin-1-ylcarbonyl)-N-
 (3-pyridylmethyl)diphenylamine 460081-60-1P,
 4-Methoxy-4'-(4-methylpiperazin-1-ylcarbonyl)-N-(3-pyridylmethyl)-3-(3-
 tetrahydrofuryloxy)diphenylamine 460081-61-2P,
 3'-(1-Butanesulfonylamino)-3-cyclopentyl-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-62-3P, 3'-Acetamido-3-
 cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-63-4P, 4-Methoxy-N-(3-pyridylmethyl)-3-(3-
 tetrahydrofuryloxy)diphenylamine 460081-64-5P,
 4-Methoxy-3-(2-(4-pyridyl)ethoxy)-N-(3-pyridylmethyl)diphenylamine
 460081-65-6P, 4-Methoxy-3-(2-methoxyethoxy)-N-(3-
 pyridylmethyl)diphenylamine 460081-67-8P, 3-Cyclopropylmethoxy-4-
 methoxy-N-(3-pyridylmethyl)diphenylamine 460081-68-9P,
 4-Methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine
 460081-69-0P, 3'-Chloro-4-methoxy-3-(2-(4-pyridyl)ethoxy)-N-(3-
 pyridylmethyl)diphenylamine 460081-70-3P, 3-[2-(4-
 Chlorophenyl)ethoxy]-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-71-4P, 3-Cyclopentyl-3'-hydroxy-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-72-5P, 3-Cyclopentyl-4'-
 hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine 460081-73-6P
 460081-74-7P, 3-Cyclopentyl-4-methoxy-4'-[2-(1-methylpyrrolidin-
 2-yl)ethoxy]-N-(3-pyridylmethyl)diphenylamine 460081-75-8P,
 3-Cyclopentyl-4-methoxy-4'-[(1-methyl-3-piperidyl)methoxy]-N-(3-
 pyridylmethyl)diphenylamine 460081-76-9P, 3-Cyclopentyl-4-
 methoxy-4'-[3-(1-methylpiperazin-4-yl)propoxy]-N-(3-
 pyridylmethyl)diphenylamine 460081-77-0P, 4-Methoxy-3-(2-
 phenoxyethoxy)-N-(3-pyridylmethyl)diphenylamine 460081-78-1P,
 3-Cyclopentyl-4-methoxy-4'-[2-(1-propanesulfonylamino)ethoxy]-N-(3-
 pyridylmethyl)diphenylamine 460081-79-2P, 4'-Chloro-3-
 cyclopentyl-4-methoxy-3'-fluoro-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-80-5P, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-81-6P, 3-Cyclopentyl-4-
 methoxy-4'-[2-(tetrahydropyran-2-yl)-2H-tetrazol-5-yl]-N-(3-
 pyridylmethyl)diphenylamine 460081-82-7P, 3-Cyclopentyl-4-
 methoxy-4'-hydroxymethyl-N-(3-pyridylmethyl)diphenylamine
 460081-83-8P, 4-Methoxy-3-[3-(4-pyridyl)prop-1-yl]oxy-N-(3-
 pyridylmethyl)diphenylamine 460081-84-9P, 3'-Chloro-4-methoxy-3-

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 (2-methoxyethoxy)-N-(3-pyridylmethyl)diphenylamine 460081-85-0P,

3-Cyclopropylmethoxy-4'-hydroxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-86-1P, 3-Cyclopentyl-4'-[2-(ethanesulfonylamino)ethoxy]-4-
 methoxy-N-(3-pyridylmethyl)diphenylamine 460081-87-2P,
 3'-Chloro-3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460081-88-3P, 3'-Chloro-4-methoxy-N-(3-pyridylmethyl)-3-(3-
 tetrahydrofuryloxy)diphenylamine 460081-89-4P,
 3'-Cyano-4-methoxy-N-(3-pyridylmethyl)-3-(3-
 tetrahydrofuryloxy)diphenylamine 460081-90-7P,


4-Difluoromethoxy-N-(3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphenylamine
 460081-91-8P, 3,4-Bis(difluoromethoxy)-N-(3-
 pyridylmethyl)diphenylamine 460081-92-9P, 4-Difluoromethoxy-N-(3-
 pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine
 460081-93-0P, 3'-Cyano-4-difluoromethoxy-N-(3-pyridylmethyl)-3-
 ((3R)-tetrahydrofuryloxy)diphenylamine 460081-94-1P,
 3'-Chloro-4-difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)-
 tetrahydrofuryloxy)diphenylamine 460081-95-2P,
 4'-tert-Butyldimethylsilyloxy-3-cyclopentyl-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460081-96-3P, N-(3-Cyclopentyl-4-
 methoxyphenyl)-N-(3-pyridylmethyl)-4-aminobenzoic acid
 460081-97-4P, N-(3-Cyclopentyl-4-difluoromethoxyphenyl)-N-(3-
 pyridylmethyl)-3-aminobenzoic acid 460081-98-5P,
 N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(3-pyridylmethyl)-3-
 aminobenzoic acid 460081-99-6P, N-[3,4-
 Bis(difluoromethoxy)phenyl]-N-(3-pyridylmethyl)-3-aminobenzoic acid
 460082-00-2P, N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(3-
 pyridylmethyl)-3-aminobenzoic acid 460082-01-3P,
 N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-4-
 aminobenzoic acid 460082-02-4P, N-(3-Cyclopropylmethoxy-4-
 difluoromethoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid
 460082-04-6P 460082-05-7P, N-(3-Cyclopropylmethoxy-4-
 methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid
 460082-06-8P, N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(3-
 pyridylmethyl)-3-aminobenzoic acid 460082-07-9P,

N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3-aminobenzoic
 acid 460082-08-0P, 3-Cyclopentyl-4-methoxy-N-(3-
 pyridylmethyl)-3'-(2H-tetrazol-5-yl)diphenylamine 460082-09-1P,


4-Methoxy-N-(3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-tetrazol-
 5-yl)diphenylamine 460082-10-4P, 3-Cyclopropylmethoxy-4-
 methoxy-N-(3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)diphenylamine
 460082-11-5P, 4-Difluoromethoxy-N-(3-pyridylmethyl)-3-((3R)-
 tetrahydrofuryloxy)-4'-(2H-tetrazol-5-yl)diphenylamine
 460082-12-6P, 3-Cyclopentyl-4-difluoromethoxy-N-(3-
 pyridylmethyl)-4'-(2H-tetrazol-5-yl)diphenylamine 460082-13-7P,
 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-pyridylmethyl)-3'-(2H-
 tetrazol-5-yl)diphenylamine 460082-18-2P, 3-Cyclopentyl-3'-
 ethanesulfonylamino-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460082-19-3P, 3-Cyclopentyl-4-methoxy-3'-(1-
 propanesulfonylamino)-N-(3-pyridylmethyl)diphenylamine
 460082-20-4P, 3-Cyclopentyl-4'-ethanesulfonylamino-4-methoxy-N-
 (3-pyridylmethyl)diphenylamine 460082-21-7P,
 3-Cyclopentyl-4-methoxy-4'-(1-propanesulfonylamino)-N-(3-
 pyridylmethyl)diphenylamine 460082-22-8P, 3-Cyclopropylmethoxy-
 3'-ethanesulfonylamino-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460082-23-9P, 4-Difluoromethoxy-3'-ethanesulfonylamino-N-(3-
 pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 460082-24-0P, 4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(3-
 pyridylmethyl)diphenylamine 460082-25-1P, 4-Methoxy-N-(3-
 pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine
 460082-26-2P, 3'-Chloro-4-methoxy-3-(2-(2-pyridyl)ethoxy)-N-(3-
 pyridylmethyl)diphenylamine 460082-27-3P, 3'-Chloro-4-methoxy-N-
 (3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)diphenylamine
 460082-28-4P, 3-Cyclopentyl-4-methoxy-4'-(5-oxo-2-
 pyrrolidinyl)methoxy)-N-(3-pyridylmethyl)diphenylamine
 460082-30-8P, 3-tert-Butyldimethylsilyloxy-3'-chloro-4-methoxy-N-
 (3-pyridylmethyl)diphenylamine 460082-31-9P, Ethyl
 N-(3-tert-butyldimethylsilyloxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-
 aminobenzoate 460082-32-0P, 3'-Chloro-3-hydroxy-4-methoxy-N-(3-
 pyridylmethyl)diphenylamine 460082-33-1P, Ethyl
 N-(3-hydroxy-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoate
 460082-34-2P, 4'-[1-(3-Bromopropyl)oxy]-3-cyclopentyl-4-methoxy-
 N-(3-pyridylmethyl)diphenylamine 460082-35-3P,
 4-Hydroxy-3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine
 460083-16-3P, 3-Cyclopentyl-4-methoxy-4'-[2-(2-
 propanesulfonylamino)ethoxy]-N-(3-pyridylmethyl)diphenylamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of C-organooxy- and N-substituted aniline and diphenylamine
 analogs as phosphodiesterase 4 inhibitors useful for enhancing
 cognition)
 RN 460080-72-2 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyl-4-methoxyphenyl)-N-phenyl-
 (9CI) (CA INDEX NAME)




RN 460080-75-5 CAPLUS
 CN Benzoic acid, 2-[[3-(cyclopentyl-4-methoxyphenyl)(3-
 pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460080-77-7 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-
 (difluoromethoxy)phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX
 NAME)


L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 460080-85-7 CAPLUS
 CN Benzamide, 3-[[3-(cyclopentyl-4-methoxyphenyl)(3-
 pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460080-86-8 CAPLUS
 CN Methanesulfonamide, N-[4-[[3-(cyclopentyl-4-methoxyphenyl)(3-
 pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460080-88-0 CAPLUS
 CN Benzenemethanol, 3-[[3-(cyclopentyl-4-methoxyphenyl)(3-
 pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 460080-89-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460080-91-5 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 460080-93-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(aminomethyl)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)


RN 460081-00-9 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 460081-01-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-02-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-03-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 460080-94-8 CAPLUS
CN Phenol, 2-methoxy-5-[phenyl(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460080-96-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460080-98-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(2-aminoethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-04-3 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460081-05-4 CAPLUS
CN 3-Pyridinemethanamine, N-[1,1'-biphenyl]-3-yl-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-06-5 CAPLUS
CN Benzonitrile, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-07-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 460081-08-7 CAPLUS
CN 3-Pyridinemethanamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-09-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(tetrahydro-3-furanyl)oxy]phenyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460081-15-6 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(4-methoxyphenyl)propoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 460081-16-7 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(2-pyridinyl)propoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-17-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-19-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(1,3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460081-10-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-13-4 CAPLUS
CN Benzenemethanesulfonamide, N-[3-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-14-5 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(4-chlorophenyl)propoxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-21-4 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-23-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(2-methyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-25-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 460081-27-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(6-methyl-2-pyridinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-29-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-30-5 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


RN 460081-38-3 CAPLUS
CN 3-Pyridinemethanamine, N-[3-[2-[(4-chlorophenyl)amino]ethoxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-39-4 CAPLUS
CN Methanesulfonamide, N-[2-[4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 460081-40-7 CAPLUS
CN 1-Butanesulfonamide, N-[2-[4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 460081-41-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)





RN 460081-32-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[(3-methyl-1-piperazinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-34-9 CAPLUS
CN 4-Morpholineethanamine, N-[3-[4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 460081-36-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-[2-(4-chlorophenoxy)ethoxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-43-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460081-45-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 460081-47-4 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 460081-48-5 CAPLUS
CN 3-Pyridinemethanamine,
N-[(3-chloro-4-fluorophenyl)-N-(3-(cyclopentyloxy)-4-methoxyphenyl)-
2,6-dichloro-N-[3-(cyclopentyloxy)-4-methoxyphenyl]-
N-phenyl]- (9CI) (CA INDEX NAME)




RN 460081-49-6 CAPLUS
CN 4-Pyridinemethanamine,
2,6-dichloro-N-[(3-(cyclopentyloxy)-4-methoxyphenyl)-
N-phenyl]- (9CI) (CA INDEX NAME)




RN 460081-50-9 CAPLUS
CN 3-Pyridinemethanamine,
N-[(4-methoxy-3-[(tetrahydro-3-furanyl)oxy]phenyl)-N-(
4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460081-58-7 CAPLUS
CN Piperazine, 1-[[3-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-
pyridinylmethyl)amino]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 460081-59-8 CAPLUS
CN Piperazine, 1-[[4-[[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl](3-
pyridinylmethyl)amino]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 460081-60-1 CAPLUS
CN Piperazine, 1-[[4-[[4-methoxy-3-[(tetrahydro-3-furanyl)oxy]phenyl](3-
pyridinylmethyl)amino]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 460081-51-0 CAPLUS
CN 3-Pyridinemethanamine, N-[(4-methoxyphenyl)-N-[(4-methoxy-3-[(tetrahydro-3-
furanyl)oxy]phenyl)- (9CI) (CA INDEX NAME)




RN 460081-52-1 CAPLUS
CN 3-Pyridinemethanamine, N-[(3-[(2,3-dihydro-1H-inden-1-yl)oxy]-4-
methoxyphenyl)-N-phenyl]- (9CI) (CA INDEX NAME)




RN 460081-53-2 CAPLUS
CN Benzoic acid, 3-[(4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl)(3-
pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-61-2 CAPLUS
CN 1-Butanesulfonamide, N-[[3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-62-3 CAPLUS
CN Acetamide, N-[[3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-
pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-63-4 CAPLUS
CN 3-Pyridinemethanamine,
N-[(4-methoxy-3-[(tetrahydro-3-furanyl)oxy]phenyl)-N-
phenyl]- (9CI) (CA INDEX NAME)




RN 460081-64-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(2-methoxyethoxy)phenyl]-N-phenyl]- (9CI) (CA INDEX NAME)



RN 460081-65-6 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-(2-methoxyethoxy)phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-67-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-68-9 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[[3-(3S)-tetrahydro-3-furanyl]oxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460081-72-5 CAPLUS
CN Phenol, 4-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-73-6 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(2-cyclohexylethoxy)phenyl]-N-[3-(cyclopentylloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-74-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-[4-(2-(1-methyl-2-pyrrolidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-69-0 CAPLUS
CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-70-3 CAPLUS
CN 3-Pyridinemethanamine, N-[3-[[2-(4-chlorophenyl)ethenyl]oxy]-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-71-4 CAPLUS
CN Phenol, 3-[[3-(cyclopentylloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-75-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-[4-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 460081-76-9 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentylloxy)-4-methoxyphenyl]-N-[4-(3-(4-methyl-1-piperazinyl)propoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460081-77-0 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-(2-phenoxyethoxy)phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-78-1 CAPLUS


L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1-Propanesulfonamide, N-[2-{4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenoxy}ethyl]- (9CI) (CA INDEX NAME)




RN 460081-79-2 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-80-5 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-81-6 CAPLUS
 CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[2-(tetrahydro-2H-pyran-2-yl)-2H-tetrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 460081-85-0 CAPLUS
 CN Phenol, 4-[(3-(cyclopropylmethoxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 460081-86-1 CAPLUS
 CN Ethanesulfonamide, N-[2-{4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]phenoxy}ethyl]- (9CI) (CA INDEX NAME)




RN 460081-87-2 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460081-88-3 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[(tetrahydro-3-furanyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 460081-82-7 CAPLUS
 CN Benzenemethanol, 4-[(3-(cyclopentyloxy)-4-methoxyphenyl)(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-83-8 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(4-pyridinyl)propoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 460081-84-9 CAPLUS
 CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 460081-89-4 CAPLUS
 CN Benzonitrile, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460081-90-7 CAPLUS
 CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460081-91-8 CAPLUS
 CN 3-Pyridinemethanamine, N-[3,4-bis(difluoromethoxy)phenyl]-N-phenyl- (9CI)

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)




RN 460081-92-9 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460081-93-0 CAPLUS
CN Benzonitrile, 3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460081-94-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(3-chlorophenyl)-4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 460081-98-5 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-99-6 CAPLUS
CN Benzoic acid, 3-[[3,4-bis(difluoromethoxy)phenyl]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-00-2 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 460081-95-2 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460081-96-3 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460081-97-4 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 460082-01-3 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-02-4 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-04-6 CAPLUS
CN Benzoic acid, 3-[[3-(4-chlorophenyl)propoxy]-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-05-7 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopropylmethoxy)-4-methoxyphenyl] (3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 460082-06-8 CAPLUS
CN Benzoic acid, 3-[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl] (3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-07-9 CAPLUS
CN Benzoic acid, 3-[[4-methoxy-3-(2-methoxyethoxy)phenyl] (3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460082-11-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460082-12-6 CAPLUS
CN 3-Pyridinemethanamine, N-[3-[(3-cyclopentyl)oxy]-4-(difluoromethoxy)phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 460082-13-7 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460082-08-0 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopentyl)oxy]-4-methoxyphenyl]-N-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460082-09-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460082-10-4 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460082-18-2 CAPLUS
CN Ethanesulfonamide, N-[3-[(3-cyclopentyl)oxy]-4-methoxyphenyl] (3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460082-19-3 CAPLUS
CN 1-Propanesulfonamide, N-[3-[(3-cyclopentyl)oxy]-4-methoxyphenyl] (3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460082-20-6 CAPLUS
CN Ethanesulfonamide, N-[4-[(3-cyclopentyl)oxy]-4-methoxyphenyl] (3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 460082-21-7 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460082-22-8 CAPLUS
CN Ethanesulfonamide, N-[3-[[3-(cyclopropylmethoxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460082-23-9 CAPLUS
CN Ethanesulfonamide, N-[3-[[4-(difluoromethoxy)-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl](3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460082-27-3 CAPLUS
CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460082-28-4 CAPLUS
CN 2-Pyrrolidinone, 5-[[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 460082-30-8 CAPLUS
CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[3-[[1,1-dimethylethyl]dimethylsilyl]oxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 460082-24-0 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 460082-25-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460082-26-2 CAPLUS
CN 3-Pyridinemethanamine, N-(3-chlorophenyl)-N-[4-methoxy-3-[2-(2-pyridinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 460082-31-9 CAPLUS
CN Benzoic acid, 3-[[3-[[1,1-dimethylethyl]dimethylsilyl]oxy]-4-methoxyphenyl](3-pyridinylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460082-32-0 CAPLUS
CN Phenol, 5-[(3-chlorophenyl)(3-pyridinylmethyl)amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 460082-33-1 CAPLUS
CN Benzoic acid, 3-[(3-hydroxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460082-34-2 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(3-bromopropoxy)phenyl]-N-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 460082-35-3 CAPLUS
CN Phenol, 2-(cyclopentyloxy)-4-[phenyl(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 460083-16-3 CAPLUS
CN 2-Propanesulfonamide, N-[2-[4-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




IT 460080-74-4, Ethyl N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-3-aminobenzoate 460080-76-6, tert-Butyl N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-pyridylmethyl)-2-aminobenzoate 460080-78-8, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3-pyridylmethyl)-4'-[2-(2-tetrahydropyran-2-yl)-2H-tetrazol-5-yl]diphenylamine 460080-87-9, 4'-Amino-3-cyclopentyloxy-4-methoxy-N-(3-pyridylmethyl)diphenylamine 460080-99-3, N-(3-Pyridylmethyl)-3'-(2-(2-phthalimido)ethoxy)-3-cyclopentyloxy-4-methoxydiphenylamine (reactant; preparation of C-organooxy- and N-substituted aniline and diphenylamine analogs as phosphodiesterase 4 inhibitors useful for enhancing cognition)


RN 460080-74-4 CAPLUS
CN Benzoic acid, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460080-76-6 CAPLUS
CN Benzoic acid, 2-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 460080-78-8 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-N-[4-(2-(tetrahydro-2H-pyran-2-yl)-2H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 460080-87-9 CAPLUS
CN 1,4-Benzenediamine, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 460080-99-3 CAPLUS
CN 1H-Indole-1,3(2H)-dione, 2-[2-[3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 1999:431896 CAPLUS
 DOCUMENT NUMBER: 131:87830
 TITLE: Preparation of 3-anilino-2-cycloalkenone derivatives
 as phosphodiesterase IV inhibitors
 INVENTOR(S): Ina, Shinji; Yamana, Kenshiro; Noda, Kyoji; Akiyama,
 Toshihiko; Takahama, Akane
 PATENT ASSIGNEE(S): Nikken Chemicals Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 45 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11189577	A2	19990713	JP 1997-366196	19971225
JP 3542482	B2	20040714		

PRIORITY APPLN. INFO.: JP 1997-366196 19971225


OTHER SOURCE(S): MARPAT 131:87830
 GI




AB The title compds. [I; R1 = (un)substituted C1-8 alkyl (excluding unsubstituted methyl), C3-7 cycloalkyl, C6-10 bicycloalkyl, 3-tetrahydrofuryl, indanyl; R2 = C1-4 alkyl; R3 = H, (un)substituted C1-5 alkyl, C3-7 cycloalkyl, acyl; R4 = H, (un)substituted C1-5 alkyl, halo, R9R10NCH2 (wherein R9, R10 = C1-5 alkyl), (C2-6 alkyleneamino)methyl (wherein one of CH2 group may be replaced by one hetero atom selected from O, N, or S); R5 - R8 = H, (un)substituted C1-5 alkyl, (un)substituted Ph; X = (CR11R12)n, NR13; wherein R11, R12 = H, (un)substituted C1-5 alkyl, Ph; n = 0-2; R13 = H, (un)substituted C1-5 alkyl], which have bronchodilatory and antiinflammatory activities, are prepared Also claimed are preventives or remedies containing I for inflammatory diseases, asthma, and dermatitis and remedies containing I for atopic dermatitis, contact dermatitis, psoriasis, and urticaria (nettle rash). Thus, 3-(2-indanyloxy)-4-methoxyaniline 2.68, 2-methyl-1,3-cyclopentanedione 1.18, and p-MeC6H4SO3H 0.07 g were dissolved in 130 mL PhMe and refluxed for 20 h to give, after workup and silica gel chromatog., the title compound (II; R = H). II (R = H) and II (R = 2-quinolinylmethyl) showed IC50 of 1.4 + 10-7 and 1.2 + 10-7 M, resp., against phosphodiesterase IV. Tablet, capsule, inhalation, and ointment formulations containing specific I were given.

IT 205067-29-4P 229310-55-8P 229310-57-0P


L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 229310-62-7P 229310-67-2P 229310-72-9P
 229310-79-6P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of alicycloalkenone derivs. as phosphodiesterase IV inhibitors for treatment of inflammations, dermatitis, asthma, psoriasis, and urticaria)
 RN 205067-29-4 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 229310-55-8 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 229310-57-0 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 RN 229310-62-7 CAPLUS
 CN 2-Cyclohexen-1-one, 3-[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl](2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 229310-67-2 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl](4-pyridinylmethyl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 229310-72-9 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl](4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 229310-79-6 CAPLUS
 CN 2-Cyclohexen-1-one, 3-[[3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl](4-pyridinylmethyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 1998:178214 CAPLUS
 DOCUMENT NUMBER: 128:257226
 TITLE: Preparation of 3-anilino-2-cycloalkenone as phosphodiesterase inhibitors
 INVENTOR(S): Ina, Shinji; Yamana, Kenjiro; Noda, Kyoji
 PATENT ASSIGNEE(S): Nikken Chemicals Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10072415	A2	19980317	JP 1997-181884	19970624
CA 2295106	AA	19981230	CA 1997-2295106	19971225
WO 9858901	A1	19981230	WO 1997-JP4857	19971225
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 994100	A1	20000419	EP 1997-950410	19971225
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
US 6235736	B1	20010522	US 2000-446822	20000320
PRIORITY APPLN. INFO.:			JP 1996-184230	A 19960626
			JP 1997-181884	A 19970624
			WO 1997-JP4857	W 19971225

OTHER SOURCE(S): MARPAT 128:257226
 GI




AB The title compds. [I: R1 = (un)substituted C1-8 alkyl, C3-7 cycloalkyl, C6-10 bicycloalkyl, etc.; R2 = C1-4 alkyl; R3 = H, (un)substituted C1-5 alkyl, acyl, C3-7 cycloalkyl; R4 = H, halo, (un)substituted C1-5 alkyl; R5-R8 = H, (un)substituted C1-5 alkyl or Ph; X = (CH2)n, NR11; R11 = (un)substituted C1-5 alkyl; n = 0-2] are prepared. I have a potent phosphodiesterase (PDE) IV inhibitory, antiasthmatic and anti-inflammatory activities. Thus, 3-cyclopentyl-4-methoxyaniline (preparation given) was reacted with 1,3-cyclopentadione in the presence of p-TsOH to give 80.4% I (R1 = cyclopentyl, R2 = Me, R3-R8 = H, X = none), which showed IC50 of 1.6 X 10-6 M against PDE IV. A formulation containing I are also prepared
 IT 205067-29-4P

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 1994:269853 CAPLUS
 DOCUMENT NUMBER: 120:269853
 TITLE: Preparation of trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
 INVENTOR(S): Beley, Nigel Robert Arnold; Millican, Thomas Andrew
 PATENT ASSIGNEE(S): Celltech Ltd., UK
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325517	A1	19931223	WO 1993-GB1266	19930615
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5340827	A	19940823	US 1993-77283	19930614
US 5550137	A	19960827	US 1993-77284	19930614
CA 2114114	AA	19931223	CA 1993-2114114	19930615
CA 2114114	C	20050503		
AU 9343470	A1	19940104	AU 1993-43470	19930615
AU 670949	B2	19960808		
EP 607373	A1	19940727	EP 1993-913367	19930615
EP 607373	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06509820	T2	19941102	JP 1994-501297	19930615
JP 3634861	B2	20050330		
AT 150447	E	19970415	AT 1993-913367	19930615
ES 2102036	T3	19970716	ES 1993-913367	19930615
US 6096747	A	20000801	US 1996-654180	19960528
PRIORITY APPLN. INFO.:			GB 1992-12673	A 19920615
			GB 1992-12693	A 19920615
			US 1993-77284	A3 19930614
			WO 1993-GB1266	A 19930615

OTHER SOURCE(S): MARPAT 120:269853
 GI




AB Title compds. I (Y = halo, R10 wherein R1 = (substituted) alkyl; R2 = (substituted) cycloalkyl, cycloalkenyl, polycycloalkyl; Z = NR3CO, R3NCO

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 3-anilino-2-cycloalkenone as phosphodiesterase inhibitors)
 RN 205067-29-4 CAPLUS
 CN 2-Cyclopenten-1-one, 3-[(3-(cyclopentyloxy)-4-methoxyphenyl)(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 wherein R3 = H, alkyl, aralkyl; R4 = aryl, heteroaryl; X = O, S, CH2, NR5 wherein R5 = H, alkyl; n = 0-3) salts, solvate and hydrates thereof, useful for prophylaxis or treatment of inflammatory disease, are prep. To 3-(cyclopentyloxy)4-methoxyaniline (prepn. given) in anhyd. pyridine was added BzCl followed by N,N-dimethylaminopyridine to give I (Y = MeO, R2X = cyclopentyloxy, Z(CH2)nR4 = BzNH). I showed phosphodiesterase IV inhibition and antiinflammatory activity.
 IT 154464-20-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as phosphodiesterase IV inhibitor)
 RN 154464-20-7 CAPLUS
 CN 4-Pyridinecarboxamide, N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-phenyl- (9CI) (CA INDEX NAME)



=> FIL REG

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.87	208.06

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.84	-5.84

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 17:07:31 ON 08 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0

DICTIONARY FILE UPDATES: 7 DEC 2005 HIGHEST RN 869534-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added. *

```

7  8  9  14  15  16  17  23
ring nodes :
1  2  3  4  5  6  13  18  19  20  21  22
chain bonds :
2-15  3-14  6-7  7-8  7-13  8-9  14-16  15-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-18  13-22  18-19  19-20  20-21  21-22
exact/norm bonds :
2-15  3-14  6-7  7-8  7-13  8-9  14-16
exact bonds :
15-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-18  13-22  18-19  19-20  20-21  21-22

```

Match level :

```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  13:Atom
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS 24:CLASS

```

Generic attributes :

9:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :

Node 9: Limited

C,C5

N,N1

O,O0

S.S0

=> d his

(FILE 'HOME' ENTERED AT 17:01:45 ON 08 DEC 2005)

FILE 'REGISTRY' ENTERED AT 17:05:15 ON 08 DEC 2005

L1 STRUCTURE UPLOADED

L2 11 S L1

L3 401 S L1 FULL

L4 401 S L3 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 17:05:40 ON 08 DEC 2005

L5 8 S L4

FILE 'REGISTRY' ENTERED AT 17:07:31 ON 08 DEC 2005

L6 STRUCTURE UPLOADED

=> s 16 subset=13 full

FULL SUBSET SEARCH INITIATED 17:07:53 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS


1 ANSWERS

SEARCH TIME: 00.00.01

L7 1 SEA SUB=L3 SSS FUL L6

=> d

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 651022-54-7 REGISTRY
ED Entered STN: 17 Feb 2004
CN Benzoic acid, 3-[(3-hydroxy-4-methoxyphenyl)(3-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[(3-Hydroxy-4-methoxyphenyl)((3-pyridyl)methyl)amino]benzoic Acid
FS 3D CONCORD
MF C20 H18 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.32	248.38

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-5.84

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 17:08:01 ON 08 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 7 Dec 2005 (20051207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 17
L8 1 L7

=> d ibib abs hitstr

ACCESSION NUMBER: 2004:80654 CAPLUS
DOCUMENT NUMBER: 140:128150
TITLE: Preparation of selective phosphodiesterase 4 inhibitors, including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses
INVENTOR(S): Schumacher, Richard A.; Hopper, Allen T.; Tehim, Ashok; Hess, Hans-Jurgen Ernst; Unterbeck, Axel; Kuester, Erik; Brubaker, William Frederick, Jr.;
Dunn, Robert F.
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009552	A1	20040129	WO 2003-US22543	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492907	AA	20040129	CA 2003-2492907	20030721
US 2005119225	A1	20050602	US 2003-622833	20030721
BR 2003012999	A	20050607	BR 2003-12999	20030721
EP 1539697	A1	20050615	EP 2003-765748	20030721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2005000870	A	20050331	NO 2005-870	20050218
PRIORITY APPL. INFO.: US 2002-396725P P 20020719				
WO 2003-US22543 W 20030721				

OTHER SOURCE(S): MARPAT 140:128150
GI



AB PDE4 inhibition (no data) is achieved by novel compds., e.g., ether-functionalized N-substituted aniline and diphenylamine analogs (shown as I; variables defined below; e.g. II). Although the methods of preparation are not claimed, >40 example preps. are included. For example, II was prepared by arylation of N-[(3-pyridyl)methyl]-3-cyclopentyl-4-methoxyaniline by iodobenzene using NaOtBu, Pd2dba3, and PtBu3 in toluene. In a 'passive avoidance in rats' test, an in vivo test for learning and memory, the amnesic effect of MK-801 is reversed in a statistically significant manner by actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine, ED range = 0.5 to 2.5 mg/kg, i.p.; and N-(3-cyclopentyl-4-methoxyphenyl)-N-(3-pyridylmethyl)-3-aminobenzoic acid, ED range = 0.1 to 2.5 mg/kg, i.p.]. In a 'radial arm maze task in rats' test, an in vivo test for learning and memory, the amnesic effect of MK-801 on working memory is reversed in a statistically significant manner by the administration of actual test compds. in a dose-dependent fashion [e.g., 3-cyclopentyl-4-methoxy-N-(3-pyridylmethyl)diphenylamine, ED = 2.5 mg/kg, i.p.; p<0.01]. For I: R1 is H, alkyl having 1-4 C atoms (un)substituted by ≥ 1 halo; R2 is C1-12 alkyl, C3-10 cycloalkyl, C4-16 cycloalkylalkyl, C6-14 aryl, C6-14-aryl-C1-5-alkyl, a partially unsatd. carbocyclic group having 5-14 atoms, a C5-10 heterocyclic group, or a heterocycle-alkyl group; R3 is H, C1-8 alkyl, a partially unsatd. carbocycle-alkyl group, C7-19-aryl-C1-5-alkyl, or heteroarylalkyl; R4 is H, C3-10 cycloalkyl, C6-14 aryl, or heteroaryl having 5-10 ring atoms; addnl. details are given in the claims.
IT 651022-54-7P, 3-[(3-Hydroxy-4-methoxyphenyl){(3-pyridyl)methylamino}benzoic Acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of selective phosphodiesterase 4 inhibitors,

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
including ether-functionalized N-substituted aniline and diphenylamine analogs, for cognition enhancement and other uses)
RN 651022-54-7 CAPLUS
CN Benzoic acid, 3-[(3-hydroxy-4-methoxyphenyl){(3-pyridylmethyl)amino}-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.39

253.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.73

-6.57

STN INTERNATIONAL LOGOFF AT 17:08:19 ON 08 DEC 2005